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A^bstracts 
Abstract 
Conventional drug delivery formulations have unquestionably contributed immensely to 
the treatment of a variety of diseases but the emergence of highly potent and specific 
biological therapeutics necessitated smart delivery systems to accomplish sustained and 
target specific delivery. A truly intelligent drug delivery system must address the need for 
intracellular transport, biocompatibility, specific targeting, while integrating the 
responsive behavior to physiological environments and recognitive feed back control. 
Systems offering controlled drug delivery offer a new lease of life to drug molecules by 
facilitating nearly constant drug levels at the site of action, prevention of peak valley 
fluctuations, eventually reduction in dosage of drugs, reduced dosage frequency, etc. 
Various natural and synthetic polymers have played a remarkable role in the 
advancement of drug delivery technology but in view of the biocompatibility, 
biodegradability and ease of preparation, the fibrin-based systems continue to remain in 
the focus of researches. Fibrin-based sealants are currently used widely for hemostasis, 
wound closure and tissue engineering and considered highly promising as drug delivery 
systems. The currently used fibrin-based systems comprise human fibrin (autologous, 
where possible) and human recombinant thrombin and transgutaminase, yet the risk of 
transmission of infectious diseases and immunological complications persist. Work 
presented in the thesis describes a novel strategy of preparing fibrin crosslinked plasma 
beads as potential carriers of drugs and antigens. 
Plasma clots in beaded form were prepared from blood plasma obtained from 
rabbits/mice in presence of EDTA. The plasma was enriched with CaCl2 and immediately 
transferred in the form of tiny droplets on a slide covered with Parafilm, with the help of 
a micropipette. Clot formation was accomplished by incubating the slides under moist 
conditions at 37 V . Aliquots of 0.5-10 |il plasma were used for the preparation of the 
beads whose average diameters varied between 1.0 and 2.75 mm. Beads prepared with 
smaller volumes of plasma were essentially spherical while the larger beads appeared 
more like flattened discs. For most of the experiments beads prepared using 3.0 \i\ plasma 
(1.9 mm diameter) were used. The polypeptide composition of the beads, as revealed by 
SDS-PAGE, was comparable with that of plasma suggesting that all the plasma proteins 
were retained in the beads without getting crosslinked to other protein during bead 
formation. The beads were porous and released both the entrapped proteins and drugs 
gradually under simulated physiological conditions. The release kinetic profiles of 
proteins suggested lack of discrimination between large and small molecular weight 
molecules. In contrast marked differences were observed in the release of small sized 
entrapped drugs. Daunorubicin for example was released more rapidly than tetracycline 
but the release rate of amphotericin B was very low. Treatment of the plasma beads with 
glutaraldehyde, that resulted in crosslinking of the bead proteins, also decreased the drug 
release in a concentration dependent manner. A preliminary in vivo study with 
cefotaxime suggested that the antibiotic is released gradually when administered in mice 
after entrapment in the plasma beads 
The ability of C. albicans antigen entrapped in the fibrin crosslinked plasma beads to 
elicit humoral and cell-mediated immune response as well as to offer protection against 
challenge by the fungus was also investigated. In order to further lower the release rate 
from the fibrin beads preparations of the partially purified antigen was either pre-
encapsulated in liposomes prepared using phosphatidyl choline and cholesterol or pre-
entrapped in PLGA microspheres. The antigen used in the study (Cp) was the 60-80 
percent ammonium sulfate saturated preparation of the C.albicans lysate that contained a 
number of proteins ranging in molecular weight between 25-95 kDa. 
Groups of mice were immunized with Cp alone, encapsulated in the liposomes (Lip-Cp), 
entrapped in the fibrin crosslinked plasma beads (Fib-Cp) or encapsulated in liposomes 
and entrapped in fibrin beads (Fib-Lip-Cp). Additional controls comprising the antigen 
emulsified with Incomplete Freund's Adjuvant (IFA-Cp), the plasma beads containing no 
Cp (Sham-Fib) and only PBS were also included. Maximum increase in total IgG levels 
were observed in the animals immunized with Fib-Lip-Cp followed by Lip-Cp and Fib-
Cp on day 10 post immunization. Compared to the groups receiving PBS or the sham 
beads, those injected with Cp revealed significantly higher level of circulating IgG. The 
IgG levels rose markedly when a combination of the incomplete Freund's adjuvant and 
Cp was administered, although the levels in the later were also clearly lower than those 
in the other three groups in the order Fib-Lip-Cp> Lip-Cp>Fib-Cp> Cp>. Five days post 
booster, the levels of total IgG in all the Cp immunized groups were proportionately 
increased with Fib-Lip-Cp clearly showing highest level. The antibody isotype analysis 
data revealed a marked increase IgG2a level in Lip-Cp, Fib-Cp and Fib-Lip-Cp groups as 
compared to other groups. The IgG2a levels of group receiving Fib-Lip-Cp were 
significantly higher when compared to those of Lip-Cp and Fib-Cp. Besides IgG2a, the 
other predominant isotype generated by Fib-Lip-Cp was IgGl. Lip-Cp and Fib-Cp 
formulations also upregulated IgGl level in the sera of immunized animals but to a lower 
extent. 
Stimulation of cell mediated immune response was also evident in the animals receiving 
various preparations of the Cp as strengthening of DTH response, measured as increase in 
foot pad thickness. The increase was in order Fob-Lip-Cp>Lip-Cp>Fib-Cp>IFA-Cp>Cp. 
Groups receiving sham fibrin beads and PBS, used as controls, showed very little 
stimulation. When peritoneal macrophages isolated from the immunized mice belonging 
to various groups were cultured in complete RPMI and incubated with the soluble 
formulations of Cp either for 5 or 6 days, generation of highest NO in response to 
immunization was observed in animals receiving Fib-Lip-Cp followed by those 
administered Lip-Cp and Fib-Cp. Marked up regulation of inducible NO synthase (iNOS, 
N0S2) in the macrophages may be involved in the Fib-Lip-Cp induced activation of 
APCs 
The CM! response generated by the Cp formulations was further substantiated by the 
measurement of the ability of various formulations of antigen to stimulate the type 1 
cytokine IFN-y levels in culture supernatants of splenocytes isolated from immunized 
mice, on day 5 post boosters. The Fib-Lip-Cp form.ulation was again most effective in 
inducing the synthesis of IFN-y. Among other forms of Cp preparations used, Lip-Cp and 
Fib-Cp caused marked increase in level of IFN-y. Animals immunized with free form of 
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Cp failed to elicit significant level of IFN-y. IL-4 secretion, The levels in cells cultures 
supematants derived from Fib-Lip-Cp group were however lower as compared to those 
immunized with the Lip-Cp (IL-4,133 pg/ml) and that of Fib-Cp (IL-4, 135 pg/ml). 
The potential of various forms of Cp to induce the proliferation of antigen-specific T 
lymphocytes isolated from spleens w?s also studied. The T lymphocytes from mice 
immunized with Fib-Lip-Cp again revealed high proliferation rates followed by those of 
Lip-Cp and Fib-Cp groups, when compared with those from animals immunized with 
IFA-Cp or free form of Cp. 
Flow cytometric analysis was conducted to evaluate the expression of CD80 and CD86 
on the surface of APCs isolated from groups of animals immunized with Fib-Lip-Cp and 
Fib-Cp showed significantly higher level of their expression (CD80, 9.4% and CD86, 
14%). In contrast, the APCs isolated from animals immunized with Fib-Cp expressed far 
lower levels both of CD80 and CD86. Study of CD4^ and CD8* positive T-cells in the 
splenocytes isolated from the animals immunized with Fib-Lip-Cp also revealed marked 
upregulation of both (CD4'^ , 12.5% and CDS'", 8.2%), when compared with the Fib-Cp 
form of antigen. 
Finally the ability of various Cp formulations to protect mice challenged with live C. 
albicans cells was investigated. At the challenge dose of yeast cells administered (1 x 10* 
cells/animal), the fungus was fatal to the non-immunized mice and all the animals in the 
group died in 10 days. Fib-Lip-Cp offered most significant protection against the /.v. 
challenge and all the animals survived 10 days post challenge and about 50 percent 
survival was recorded after 30 days. The prophylactic potential of Fib-Lip-Cp, Lip-Cp 
and Fib-Cp against systemic candidiasis was further investigated by determining the 
residual fungal load in various vital organs of the mice infected with C. albicans. The 
animals were sacrificed on day five post infection. Animals immunized with Fib-Lip-Cp, 
Lip-Cp and Fib-Cp. revealed several fold lower fungal load in the systemic circulation 
when compared with the free Cp immunized animals. 
IV 
PoIy(D, L-lactide-coglycolide) (PLGA) polymers are among the most frequently used 
biomaterial owing to their excellent biocompatibility and biodegradability and approval 
by the Food and Drug Administration, USA (FDA) for human use. An attempt was also 
made to pre-entrap the C. albicans antigen, in PLGA microspheres, prior to their 
entrapment in the fibrin crossiinked plasma beads, for use as an effective delivery system. 
The design of the experiments was essentially similar to that describe earlier for the 
fibrin-based dual delivery system employing liposomes. As mentioned earlier, separate 
set of ex{)eriments was necessitated due to large number of animals and samples for 
analysis required in the study. As observed in case of the previous study with liposomes, 
pre-entrapment in the PLGA microspheres, prior to plasma bead entrapment, resulted in 
marked improvement in the ability of Cp to induce both humoral and cell-mediated 
immunity in the mice. This was evident in studies in which total IgG, IgG2a and 
IgGltitres as well as DTH, NO and IFN-y levels were measured in mice immunized with 
various Cp formulations. It was apparent that while immunization with PLGA 
microsphere-entrapped Cp resulted in marked enhancement in the level of the above, as 
compared to the groups receiving Cp alone, IFA-Cp and even Fib-Cp, the group 
receiving the PLGA entrapped Cp further entrapped in the plasma beads evoked 
maximum response. The mice receiving Fib-PLGA-Cp showed maximum expression of 
CD80 and CD86 markers on the surface of their APCs and CD4* and CD8^ on their T cell 
populations. This suggested that the dual entrapment of the antigen is highly effective, 
although entrapment of the antigen in plasma beads or in the PLGA microspheres alone 
was more effective in inducing the immune response as compared to that with Cp alone 
or in combination with the adjuvant. The additive advantage of the Cp entrapment in 
PLGA microspheres and plasma beads was also evident in protection studies in the 
animals challenged post immunization with various antigen formulations. The data on 
day 15 post infection showed almost 90, 80 and 60 percent survival of animals 
immunized with Fib-PLGA-Cp, PLGA-Cp and Fib-Cp respectively. No animal survived 
in the control groups beyond day 15 post infection. On the day 30 post challenge with C. 
albicans cells, the survival rate of animals immunized with Fib-PLGA-Cp was 60%, 
while it was 50% for PLGA-Cp and only 40% in case of Fib-Cp. Only 20 and 30 percent 
of the animals survived in groups immunized with free Cp and IFA-Cp. The prophylactic 
potential of Fib-PLGA-Cp, PLGA-Cp and Hb-Cp against systemic candidiasis was also 
further investigated by determining the residual fungal load in various vital organs of 
animals challenged will. C. albicans cells. The animals were sacrificed on day five post 
challenge m ord wrmii.e the fungal load in systemic circulation as well as in 
various yital orgai.o. Animals treated with Fib-PLGA-Cp, PLGA-Cp and Fib-Cp has 
several folG"lowcr fiingw' load in the s>stemic circulation when compared with free Cp 
immunized animals. The fungai buiden in the spleen and kidney expressed in form of 
CFU in the animals that si " up to day 30 was also lower in the Fib-PLGA-Cp and 
PLGA-Cp and Fib-Cp groups as compared to mice treated with free Cp. 
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1.1. Drug Delivery Systems 
The primary objective of a drug delivery system is to release therapeutics at a 
predetermined anatomical site and maintain circulating drug concentration within a 
therapeutic band for the required duration. Drugs administered orally, parenterally or 
by other means enter the blood stream and gain access to almost all tissues of the 
body. The drugs disseminate from the blood to most tissues by crossing the 
endothelial barriers or by entering through the endothelial gaps in tissues with leaky 
vasculature. This evidently leads to unwanted delivery to non-target tissues, 
necessitating high dosages and at times results in serious side effects. Controlled drug 
delivery systems have therefore acquired seminal significance in pharmaceutical 
research. Drug delivery systems offer numerous advantages including minimization of 
peak-valley fluctuations, reduction in the drug dosage, lowering of dosage frequency, 
decrease in side effects and improved patience compliance. 
The earliest drug delivery systems investigated were polymer carriers for 
accomplishing spatiotemporal release of therapeutics, both pulsatile dose delivery 
products and implanted reservoir systems. Various polymers including cellulose 
derivatives, poly(ethylene glycol) (PEG) and poly (N-vinyl pyrrolidone) are in use 
for over five decades and their early applications include use in drug sprays, dip 
coating and encapsulation (Rowe et al., 2005). A large number of other natural and 
synthetic drug delivery systems have also been investigated with varying success. 
From the drug delivery perspective, polymer devices can be classified into i. 
Diffusion controlled (monolithic devices) ii. Solvent activated (swelling or 
osmotically controlled devices) iii. Chemically controlled (biodegradable) and iv. 
Triggered systems (Liechty et al., 2010). 
1.2. Biodegradable Polymeric Systems 
Biodegradable polymers have emerged as one of the most important polymeric 
systems with remarkable drug delivery potential. Although molecules that undergo 
bio-erosion are also used interchangeably with biodegradation, the two differ; erosion 
occurs by the dissolution of chain fragments in non crosslinked systems without 
chemical alterations to the molecular structure, while biodegradation occurs through 
the covalent bond cleavage by a chemical reaction. Both biodegradation and erosion 
can occur as surface or bulk process. In surface degradation the polymeric matrix is 
progressively remove from the surface but the polymer volume fraction remains 
almost unchanged. In contrast, during bulk degradation no significant changes occur 
in the physical size of the polymer until it is nearly completely degraded or eroded. 
To be biodegradable, a polymer requires hydrolysis, usually enzymatic, of a 
susceptible bond either in the backbone or crosslinker. Most of the biodegradable 
carriers rely on the cleavage of ester bond, ester derivatives like poly (lactic/glycolic 
acid) and poly (s-caprolactone) or peptide bond. Other hydrolysable bonds include 
those of poly(anhydrides), poly(orthoesters), poly(phophoesters) (Park et al, 1993). 
Biodegradable polymers include polymers of diverse origin such as polysaccharide, 
protein and synthetic polymers. Among the polysaccharide polymers alginate, 
dextran, hyaluronic acid, chitosan and cellulose have been studied extensively. 
Gelatin, collagen, albumin and silk fibroin are proteinaceous studied in detail. 
Synthetic polymers investigated for drug delivery include polyphosphazene, 
polyurethane, polycaprolactone, polyorthoester. The polymers and their applications 
in delivery of pharmaceuticals are discussed in some detail below. 
1.2.1. Polysaccharide Polymers 
1.2.1.1. Alginates 
Commercial alginates are extracted from brown algal species which include 
Laminaria hyperborean, Ascophyllum nodosum, and Macrocystis pyrifera. It is a 
linear polysaccharide containing varying amounts of 1, 4-linked P-D-mannuronic acid 
and a-L-guluronic acid (Fig. 1.1 a.). The exact composition and residue sequence of 
alginates vary depending on the source. Due to its biocompatibility, low toxicity, 
nonimmunogenic nature, relatively low cost and ready gelation with divalent cations 
such as Ca, it has been widely used in drug delivery and tissue engineering 
applications (George et al, 2006). Cross-linking with various types of molecules has 
been carried out to control the mechanical and/ or swelling properties of alginate gel. 
The high porosity of alginates makes it more suitable for the entrapments of cells and 
large molecular weight pharmaceuticals (Smidsrod et al., 1990). Alginate has also 
been studied as an injectable delivery vehicle of cells (Atala et ai, 1994), proteins 
(Wee et al, 1998), hormones (Silva et ai, 2006) and various growth factors 
(Kolambkare^a/., 2010). 
1.2.1.2. Dextrans 
Dextrans are a complex, high molecular weight, branched polymers of D-glucose 
(Fig. 1.1b), available in a wide range of molecular dimensions and types. Dextrans 
have been investigated for numerous applications, including as plasma expanders and 
blood substitutes in addition to their use as delivery vesicles of drugs. Dextran based 
microparticles have been used for the delivery of recombinant human bone 
morphogenetic protein-2 (rhBMP2) (Chen et al., 2005). Acetylated dextran micro 
particles are potent in vitro delivery platforms for vaccine adjuvants (Bachelder et ai. 
2010). Qi et al. (2010) prepared composite BSA-dextran nanoparticles for the 
delivery of an anticancer drug doxorubicin for the treatment of murine ascites 
hepatoma H22 tumor-bearing mice. The nanoparticles decreased the toxicity of 
doxorubicin and significantly increased the survival of the tumor-bearing mice. 
1.2.1.3. Hyaluronic Acid 
Hyaluronic (HA) acid is a naturally occurring non-sulfated glycosaminoglycan 
(Fig. 1.1c.) and is the main macromolecular component of the intercellular matrix. HA 
present in most of the connective tissues, is water soluble and forms extremely 
viscous solutions having unique viscoelastic properties. It is actively involved in 
many biological process such as regulating extracellular matrix organization, 
modulating cell migration and differentiation during embryogenesis and metabolism. 
HA has been used widely in tissue engineering, wound dressing, lubrication and as 
mechanical support in osteoarthritis and in various implantations (Choi et al., 1999; Ji 
et al., 2006; Ng et al., 2005). HA has also been extensively utilized in cosmetic 
products because of its unique viscoelastic properties and excellent biocompatibility 
(Manuskiatti et al., 1996). Crosslinked HA prepared with the help of various 
physical and chemical procedures (Villar et al., 1995) shows excellent potential in 
ophthalmic (Jarvinen e^  a/., 1995; Bucolo e/a/., 1999), nasal (Morimoto e/a/., 1991; 
Lim et al., 2002) and parenteral drug delivery (Drobnik, 1991; Peer et al., 2003). 
Some studies describing the use of HA in gene delivery are also available (Yun el al., 
2004; Kim et al, 2003). HA is generally thought to act either as a mucoadhesive and 
retains the drug at its site of action/absorption or to modify the in vivo 
release/absorption rate of the associated therapeutic agent. HA also has interesting 
applications in topical delivery of drugs (Brown et al, 2005). 
1.2.1.4. Chitosan 
Chitosans are natural, biocompatible and biodegradable polymers (Fig. 1.Id.) and 
hence considered safe delivery materials for several drug. In addition, chitosans are 
highly water-soluble requiring only simple and mild treatments to transform them into 
usefiil delivery systems also suitable for labile drugs. 
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Fig. 1.1. Partial structure of alginate (a), dextran (b), hyalouronic acid (c) and chitosan (d). 
Chitosans are available in a wide range of molecular weights and are easily modified 
chemically and can be coupled with various ligands providing flexibility in 
formulation development. Chitosans also provide absorption promoting effect that 
prolongs the contact time between drugs and cell membrane (Wood et al, 1985). In 
addition, nano-sized chitosan preparations facilitate the uptake of drugs like cisplatin 
through the payer's patches of M cells (Qi and Xu, 2006). The nano-sized particle 
dimensions together with absorption enhancing effect of chitosan remarkably improve 
drug bioavailability (Takeuchi et al., 2001; Vila et al, 2002). Furthermore, chitosans 
offer versatile routes of administration, especially the preferred non-invasive routes. 
i.e. peroral, nasal, and ocular mucosal. Some chitosans appear to be good adjuvant 
and also useful in vaccine delivery (Kreuter, 1995). 
1.2.2. Proteinic Polymers 
1.2.2.1. Collagen 
Collagens are a group of naturally occurring proteins found exclusively in animals, 
especially in the muscle and connective tissues of mammals (Muller and Werner, 
2003). Collagens are the main components of connective tissue, and the most 
abundant proteins in mammals, making up to about 25-35 percent of the whole-body 
protein content (Di Lullo et al, 2002). Collagen gels are visco-elastic thereby semi-
solid, which makes them conveniently injectable and biocompatible drug delivery 
matrices. They can even be induced to flow under stress (e.g., extrusion from a 
syringe) (Wallace et al, 1988; Wallace et al, 1989; Rosenblatt et al, 1993; Chow et 
al, 1985). In addition, they exhibit good cell and tissue compatibility (Wallace et al, 
1988; Kligman, 1988; Stegman et al, 1988; Stegman et al, 1987) and thus do not 
interfere with normal body functions. When injected into the site of interest, collagen 
matrices release the entrapped pharmaceuticals in their surroundings in a controlled 
manner (Wallace and Rosenblatt, 2003). The available forms of injectable collagen 
gels include suspensions of collagen fibers (Wallace et al, 1988; Rosenblatt et al, 
1993) and non-fibrillar, viscous aqueous solutions (Chow et al, 1985). Small 
molecular weight drugs and therapeutic proteins have also been used with the fibrillar 
suspensions or viscous collagen solutions (Wallace and Rosenblatt, 2003). The 
collagen network readily retains various cells by physical entrapment (Wallace and 
Rosenblatt, 2003) and have also been employed as scaffolds in tissue engineering, 
delivery matrices for cells and in gene therapy (Wallace and Rosenblatt, 2003). 
1.2.2.2 Gelatins 
Gelatin is a translucent protein, derived from the collagen from animal skin and 
bones and commonly used as a gelling agent in food, pharmaceuticals, photography. 
and cosmetic manufacture. Gelatin is a non-toxic, biodegradable, biocompatible, non-
carcinogenetic, non-immunogenic and inexpensive natural polymer. Gelatin gels can 
be readily prepared in a wide range of shapes such as sponges, microsphere and 
injectable hydrogels (Malafaya et al, 2007). Gelatin formulations have been largely 
investigated for nano and microparticular drug delivery (Hashida et al, 1979) and 
several in several pharmaceutical, medical as well as gene delivery applications 
(Tabata et al, 1996; Miyoshi et al, 2005). The highly water soluble nature of gelatin 
necessitates crosslinking to facilitate controlled release of entrapped drugs and 
formaldehyde (Digenis et al, 1994), glutaraldehyde (Tanaka et al, 1963) or other 
bifunctional reagents (Raymond et al, 1990) are generally used for the purpose. 
Chondrocyctes entrapped in the gelatin gels were shown to produce cartilage specific 
matrix for over 21 days in vitro cultures and viability of the cells was also maintained. 
Several commercial gelatin-based carriers for drug delivery like Gelfoam® with 
potential in tissue engineering are also currently available (Awad et al, 2004). 
1.2.2.3 Serum albumin 
Albumin is the most abundant protein in blood plasma of higher animals and 
constitutes up to 50% of total mass of plasma. Albumin plays an important role in 
binding and transport endogenous and exogenous substances, including those which 
are toxic in unbound state. Albumin has the ability to bind to a variety of molecules 
including fatty acids and a variety of drugs (Spector, 1975; Koch-Weser and Sellers, 
1976) and serves as a circulating depot of several compounds (Kragh-Hansen, 1990). 
Nearly all of human body cells degrade albumin making the protein a highly suitable 
for biomedical applications (Prinsen and de Sain-van der Velden, 2004). Serum 
albumin can be easily processed into variety of forms including microsphere, 
membranes, nanofibres, nanospheres (Nair and Laurencin, 2007). Human serum 
albumin microspheres have potential as a slow release drug delivery system (Kramer, 
1974; Kandzia et al, 1984). They offer advantages over other type of polymeric 
microspheres in being nonantigenic, readily metabolizable with potential to bind a 
variety of drugs in relatively non specific fashion (Kramer, 1974). They have also 
been studied as a carrier systems for several proteins and enzymes (Ovadia et al, 
1982; Kandzia et al, 1982), anticancer agents (Widder et al, 1979), steroids (Lee et 
al, 1981) and highly water soluble drugs like Ciprofloxacin (Li et al, 2001). 
Albumin conjugated with heparin was used in preparation of microsphere for some 
interesting drug delivery application. Adriamycin-loaded albumin-heparin conjugate 
microspheres (AHCMS) show an increased antitumour efficacy in L1210 tumour-
bearing mouse and the CC531 tumour-bearing rat model and reduce its acute toxicity 
(Cremers et al., 1994). 
1.2.2.4 Silk Fibroin 
Silk proteins have also been investigated as supports for sustained drug delivery due 
to their aqueous processability, biocompatibility, and biodegradability. Silk fibroin 
particles were loaded with small molecular model drugs, such as alcian blue, 
rhodamine B, and crystal violet, by simple absorption based on electrostatic 
interactions. In vitro studies revealed that the release of small molecules was 
governed by the charge they carry and structure of silk (Lammel et al, 2010). Release 
kinetics of crystal violet was shown to dependent on the secondary structure of the 
protein in the particles (Lammel et al, 2010). Silk fibroin based delivery of adenosine 
has been shown to suppress seizures in rat model (Wilz et al, 2008). In a recent study 
silk fibroin microparticles have also been used as carriers for the delivery of human 
recombinant Bone Morphogenetic Proteins (BMPs) (Bessa et al, 2010). The 
curcumin loaded chitosan nanoparticles and emodin-loaded liposomes, both coated 
with the silk fibroin proved to have higher efficacy in Her2/«ew expressing breast 
cancer cells (MDA-MB-453) (Gupta et al, 2009; Cheema et al, 2007) 
1.2.2.5. Fibrin 
Fibrinogen is a 340 kDa glycoprotein, originating in the liver and present abundantl)' 
in the blood stream of higher animals. The protein comprises three pairs of 
polypeptide chains Aa, Bp, and y that are joined together with six disulfide bridges. 
During the coagulation cascade of the fibrinogen, thrombin cleaves the peptides A 
from Aa, and B from Bp chains of fibrinogen leading to spontaneous polymerization 
of the resulting fibrin monomers. This is followed by fibrin protofibril associations, 
causing the formation of loosely assembled clot that in turn is stabilized by covalent 
crosslinking by plasma transglutaminase (factor Xllla) (Fig. 1.2.). Under 
physiological conditions the protofibrils assemble in to fibres by lateral interactions 
that involve both specific, relatively weak protein protein interactions and chloride 
ions (Di stasio et ai, 1998). Gels can be formed by either protofibrils or fibres that 
form the fine and coarse clots (Fig. 1.3.). (Ferry and Morrison, 1947). The stable clot 
formed 
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Fig. 1.2. Mechanism of crosslinking in fibrin leading to clot formation (Lorand, 2007). 
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Fig.lJ. (a-c) Schematic representation of the structure of fibrin monomers and 
their assembly into protofibrils (Janmey et ai, 2009). 
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thus not only plays a haemostatic role but also acts as an initial scaffold for tissue 
regeneration, serving as a platform for cell migration and proliferation (Mosesson, 
2005). A number of plasma components including cells, growth factors and enzymes 
get entrapped in the clots formed thus (Table I). The fibrin fibres (Fig. 4.) are 
presumably the most highly extensible of the filamentous biopolymers and can resist 
stretching to more than five times their resting length without breakage. 
Fig,l,4. Scanning electron micrograph of 1 mg/ml human fibrinogen 
polymerized by 1 U/ml thrombin at pH 7.4 and 150 mM NaCl (Janmey 
et al, 2009). 
Tissue engineering technology necessitates a combination of three principal 
components; a cellular component, a stable scaffold and a bioactive 
component. Tissue engineering scaffolds need to be idealized combinations of 
mechanical properties, geometry, surface chemistry and mimic extracellur 
matrix in not eliciting immune response, provide framework for cellular 
infiltration/proliferation and be biodegradable (Ahmed et al, 2007). Fibin gels 
are flexible and the most widely used fibrin scaffolds are fibrin hydrogels, 
fibrin glues and fibrin microbeads, although other forms like fibrin sheets, and 
foams are also used for specific applications. 
Table I. Cells, growth factors and enzymes that get naturally entrapped during 
clot formation 
Components Reference 
Platelets 
Endothelial cells 
Fibroblast 
Matrix proteins 
Fibronectin 
Vitronectin 
Thrombospondin 
Growth factors 
Fibroblast Growth factor (bFGF) 
VEGFi65 
Transforming Growth factor pi 
Platelet -derived growth factor(PDGF-BB 
IGF-1 
Interleukin-ip 
Growth factor bound via heparin 
bFGF 
Epidermal growth factor (EGF) 
PDGF (-A,-B) 
Enzymes 
Plasminogen 
Tissue Plasminogen activator (tPA) 
Plasminogen inhibitor 
Thrombin 
Pondolnikove et al, 2005 
Chereshera/., 1987 
Gailitera/., 1997 
Mongonenko et al, 2002 
Vodor etal, 2002 
Bacon-Baguley, 1990 
Sahnie^a/., 1998 
Sahni and Francis, 2000 
O'kane and Ferguson, 1997 
Dohan et al, 2006 
Dohane/a/., 2006 
Sahni et al, 2004 
Bairdera/., 1985 
Higashiyamae^fl/., 1991 
Lustige^a/., 1999 
Tsurupa and Medved, 2001 
Tsurupa and Medved, 2001 
Wangerera/., 1989 
Pospisil et al, 2003 
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1. 2.2.5.1. Applications of Fibrin Matrix 
1.2.2.5.1.1. Historical 
Bergel (1909) was probably the first to envisage the use of fibrin as a hemostat. The 
subsequent use fibrin in cerebral surgery for hemostatic purpose was described in 
1915 by Grey. A report on the use of fibrin as an adhesive in peripheral nerve 
attachment in an animal model appeared about two and half decades later (Young and 
Medawaar, 1940) and Medawar along with Seddon (1943) subsequently extended its 
use to humans. Cronkite et al. (1944) are credited for using of fibrinogen and 
thrombin as biological glues during skin grafting. A concentrated fibrin containing 
sealants was used by Matras et al. (1972) during nerve transplantation in experimental 
animals. The first reports on procedures for the production of concentrated fibrin for 
use in clinically useftil sealants are credited to Gestring and Lemer (1983) and 
Sidentop et al. (1985). While commercial fibrin preparations were available starting 
from the eighties in Europe, and they were used extensively in various surgical 
specialties, approval of the fibrin sealants for use in the USA by the FDA had to wait 
till 1998. This however did not deter the US surgeons who were using blood bank 
source of concentrated fibrin along with bovine thrombin for the purpose. Fibrin 
matrices continue to be investigated for a variety of applications in addition to their 
role as sealants and a number of reviews on the subject have appeared in recent years 
(Table II). 
The first commercial fibrinogen product approved in the US was Tisseel, distributed 
by the Baxter Healthcar Corporation (Glendale, CA). The preparation contains 
fibrinogen 
11 
Table II. Reviews published on fibrin applications during 2005 to 2010 
Title Reference 
Fibrin sealant: past, present, and future: a brief review 
Fibrin as a delivery system for therapeutic 
drugs and biomolecules 
Fibrin gels and their clinical and bioengineering 
applications 
Soft materials to treat central nervous system injuries: 
evaluation of the suitability of non-mammalian fibrin gels 
Fibrin: a versatile scaffold for tissue engineering 
applications 
Fibrin: a natural biodegradable scaffold in vascular tissue 
engineering 
Fibrinogen and fibrin: scaffold proteins in hemostasis 
Modified fibrin hydrogel matrices: both, 3D-scaffolds for 
local and controlled release systems to 
stimulate angiogenesis 
The role of fibrin sealants in hepatic surgery 
Review of injectable cartilage engineering using 
fibrin gel in mice and swine models 
Fibrin in tissue engineering 
Current applications of fibrin sealant in urologic surgery 
Fibrin glues of human origin 
Fibrin structure and wound healing 
Fibrin sealant tissue adhesive-review and update 
Fibrinogen and fibrin 
Applications of fibrin sealant in surgery 
Fibrinogen and fibrin structure and fiinctions 
Fibrin and its applications 
Spotnitz, 2010 
Bresn etai, 2009 
Jarmiey et al, 2009 
Vhioetal, 2009 
Ahmed era/., 2008 
Shaikh er a/., 2008 
Lord, 2007 
Hall, 2007 
SarpeUra/., 2007 
PerettieM/., 2006 
Eyriche/a/., 2006 
Evans and Morey, 2006 
Valbonesi, 2006 
Laurens et al, 2006 
Spotnitz and Prabhu, 2005 
Weisel, 2005 
Lee & Jones, 2005 
Mosesson, 2005 
Tawil, 2005 
12 
and thrombin subjected to cryoprecipitation, lyophilization and Sephadex adsorbtion 
to minimize the risk of viral contamination and bovine aprotinin as the antifibrinolytic 
agent. American Red Cross subsequently introduced Crossseal, as the second 
generation fibrin sealant product in 2003. The product comprises fibrinogen and 
thrombin subjected additionally to solvent and detergent treatment, heat pasteurization 
and nanofiltration to ensure viral inactivation and tranexamic acid as the 
antifibrinolytic agent (Spotnitz et al, 2005). Other commercial fibrin sealant 
preparations available globally are listed in Table III. 
Table III. Fibrin products currently available commercially 
Product Manufacturer 
• Tisseel®, Tissucol 
Tisseel 
Beriplast® 
Pennsylvania 
Artiss® 
EviceF"^ 
Quixil 
CrosseaF"^ 
Cryoseal® 
VIGuard F.S. 
Tisseel Duo Quick 
Hemaseel APR, Hemaseel HMN 
Fibrin Sealant FS (Human), 
Tissucol Duo S 
Haemocomplenttan 
Hemaseel 
Bolheal 
Biocol 
TachoComb 
Duo Baxter-Immuno AG, Austria, Baxter 
Hyland Immuno, Glendale, California 
VH Kit Baxter- Immuno AG, USA 
CSL Behring, King of Prussia, 
Baxter Healthcare 
Omrix Biopharmaceuticals Ltd. New Yark, NY 
Omrix Biopharmaceuticals SA, Israel 
Ethicon Inc., Somerville, New Jersey 
Thermogenesis, Rancho Condova, California 
Vitex: VI Technologies, USA 
Baxter Hyland immuno, Glendale, California 
Haemacure, Inc., Quebec, Canada 
Baxter Healthcare, Glendele, California 
Centeon, Marburg Germaney 
APR Hemacure, Canada 
Kaketsuken Pharmaceuticals, Japan 
Bio-transformation, Lille, France 
Nycomed Pharma, Roskilde, Denmark 
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1.2.2.5.1.4. Antibiotic delivery 
Prevention of infection is the greatest challenge after bleeding control at the site of 
damage caused either by an accident or during surgery. It was therefore anticipated 
that antibiotics would be among the early candidates for investigating the drug 
delivery potential of the fibrin matrices in order to provide a local antimicrobial effect 
during tissue healing and re-absorption of the clot. 
A plethora of data is now available on the use of antibiotics in combination with fibrin 
gels including those on in vitro and in vivo studies in animals as well as in humans 
(Table IV). In a pioneering study Redl et al. (1983) prepared fibrin glue using fibrin 
reconstituted with the antibiotics, gentamycin, neomycin and polymixin and observed 
almost complete release in vitro of the entrapped antibiotics in 72 hours. Greco et al. 
(1991) similarly, entrapped ampicillin, carbenicillin, cefotaxime, ceftazidine, 
clindamycin, gentamycin, mezlocillin and tobramycin in fibrin gels and also observed 
their rapid release with over 50 percent of the drugs leaking out in first 24 hours and 
most of the drug being lost in or 48-96 hours. Cefotaxime release was also shown to 
be rapid from fibrin gels containing the entrapped drug during treatment of osteitis 
(Zilch and Lambiris, 1986). 
Release of the relatively water insoluble drugs from fibrin matrices is however slow 
and gradual over a period of time. Release of gentamycin and ciprofloxacin from the 
fibrin gels lasted up to seven days, although more than half of the drugs were released 
during the first day (Marone et al., 1999; Kram et al., 1991; Park et al., 1997). Fibrin 
sealed Dacron grafts with entrapped vancomycin (Fujimoto et al., 1997) and and 
sisomicin (Osada et al., 2000) were shown to establish high local antibiotic 
concentration only during the first post operative day in the patients. Rapid initial 
release of the entrapped antibiotic at the site during the first day is however 
advantageous in many surgical applications, especially during implantation of 
devices, in combating infections. 
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Table IV. Antibiotics entrapped in the Fibrin used for in vivo or in vitro studies 
Antibiotic Reference 
Ampicillin 
Oflaxacin 
Abrekacin sulfate 
Teicoplanin 
Debakacin 
Sisomicin 
Gentamicin 
Neomycin 
Carbenicillin 
Ceftazidin 
Clindamycin 
Vancomycin 
Cephalothin 
Metranidazole 
Bacitracine 
Gentamicin derivative 
Tobramycin 
Cefoxitin 
Ciproflaxacin 
Polymixin B 
Mupirocin 
Norflaxacin 
Ceftazydime 
Tetracycline 
Nitrofiirazone 
Cefotaxime 
Thompson and Davis, 1997; Park and Kim, 1997; 
Greco etai, 1991 
Park and Kim, 1997 
Itokazu etai, 1997 
Kram et al, 1990; Marone et al, 1999 
Thompson and Davis, 1997 
Tsunehisa et a/., 1991; Osada et al, 2000 
Thompson and Davis, 1997; Park and Kim, 1997; 
RedXetal, 1983; 
Marone et al, 1999; Kram et al, 1990; Greco et al, 199] 
Redl et al, 1983; Wantabe et al, 1994 
Thompson and Davis, 1997 
Thompson and Davis, 1997 
Van der Ham et al, 1992; Thompson and Davis, 1997; 
Greco era/., 1991 
Marone e/a/., 1999 
Deyerling et al, 1984; Marone et al, 1999 
Haverich e^  a/., 1989 
Haveriche/a/., 1989 
Carck et al, 1990; Harvich et al., 1992 
Ney et al, 1990; Greco et al, 1991 
Kram et al, 1990; Thompson and Davis, 1997 
Tsourvakas et al, 1995; Kram et al, 1990 
Thompson and Davis, 1997 
Thompson and Davis, 1997 
Thompson and Davis, 1997 
Greco etal, 1991 
Woolverton et al, 2002; Kumar et al, 2004 
Thompson and Davis, 1997 
Zilch and lambiris, 1986; Van der Ham et al, 1992 
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Woolverton et al (1999) in a more systematic study compared the release of a 
number of antibiotics (e.g. erythromycin, tetracycline and penicillin) and substantiated 
the assumption that the determining factor in their release from the gels is their water 
insolubility. Tetracycline was released from the fibrin preparation over a long period, 
presumably because the insoluble antibiotic dissolves gradually in aqueous media. 
The preparation could control peritonitis initiated by a multi-drug resistant S. aureus. 
In a subsequent study Woolverton et al. (2001) using mouse and rat models and 
demonstrated that localized delivery of tetracycline from fibrin discs controls 
peritoneal sepsis induced by S. aureus infection without any measurable systemic 
antibiotic but gave complete protection against infection for over five weeks. 
Vancomycin, a broad spectrum antibiotic against gram positive bacteria and used in 
the control of Staphylococci, was incorporated into the fibrin glue and implanted as a 
Dacron graft in the subcutaneous tissue of the anterior abdominal wall of rats 
(Fujimoto et al, 1997). Vancomycin levels in the serum were very low while those in 
the tissue surrounding the implant were high and the bactericidal levels were 
maintained over 24 hour duration. The antibiotic injected i.v. however declined 
rapidly from very high initial levels in circulation but the concentration in the tissue 
surrounding the implant remained very low. Interestingly, neither grafts got infected 
with S. aureus. In a subsequent study from the group it was shown that fibrin glue 
entrapped sisomicin release from the Dacron graft was remarkably similar to that of 
vancomycin in Sprauge-Dawley rats. In addition the prosthesis was applied to ten 
patients who underwent vascular reconstruction surgery and the serum levels of the 
antibiotic analyzed suggested a pattern comparable to that evident in the animal 
studies (Osada et al, 2000). 
Tredwell et al. (2006) in a more recent study investigated the in vitro stability and 
release of erythromycin B and cefazolin entrapped in the commercial fibrin sealant 
Beriplast. While the released erythromycin was rapidly degraded, the observed release 
profile and remarkable stability of fibrin associated cefazolin suggested the potential 
of the fibrin entrapped antibiotic in the post operafive therapy. Marone et al. (1999) 
evaluated the antibiotic activity of and elution rates from fibrin clots impregnated with 
the antibiotics vancomycin, teicoplanin, gentamicin and cephalothin. The antibacterial 
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activity was investigated using a clinical isolate of Staphylococcus epidermidis. While 
all the fibrin preparations containing the antibiotics were inhibitory during the first 24 
hours, inhibition up to four days was observed with the glycopeptide antibiotic 
teicoplanin. Higher concentration of gentamycin also persisted suggesting that the 
antibiotics can be useful both prophylactically and therapeutically in ocular surgery 
after fibrin entrapment. Kram et al. (1991) used fibrin glue entrapped ciprofloxacin, 
teicoplanin, cefoxitin and gentamycin for investigation of their leakage in normal 
saline and human serum. Inhibition of growth of S. aureus in the inoculated brain-
heart infiision and mouse lung infiision was also investigated. While all the antibiotic 
preparations were inhibitory initially, the inhibitory effect of ciprofloxacin and 
teicoplanin persisted for up to 7 days. 
1.2.2.5.1.5. Delivery of anticancer drugs 
Fibrin glue prepared from human plasma by the cryoprecipitation procedure was 
investigated for its ability to deliver several anticancer drugs, both in presence or 
absence of the protease inhibitor aprotinin (Yoshida et al, 2000). Mitomycin C, 
fluorouracil and tegafur were quickly released from the glue both in presence or 
absence of the inhibitor. Aprotinin however retarded the rate of release of etoposide, 
doxorubicin and enocitabine which were also rapidly released like mitomycin C and 
fluorouracil in absence of the inhibitor. The release rate of the drugs in presence of 
aprotinin correlated well with their hydrophobicity rather than their molecular size or 
ability to bind to the clot proteins. Fibrin sealant that released the entrapped 
carboplatin gradually over a period of 12 days was used by Simpson et al. (2002) for 
successftil transscleral delivery of the drug. The potential of fibrin sealant entrapped 
topotecan (Tsui et al, 2000) and carboplatin (Pardue et al, 2004) delivered 
subconjuctivally, in the treatment of transgenic murine retinoblastoma and 
improvement of retinal fijnction respectively has also been reported. Fibrinogen with 
its high affinity for hydrophobic surfaces can be coated on the surface of oil droplets 
for use as vehicles to deliver lipophilic drugs to sites of fibrinogen deposition, 
including malignant tumors in vivo (DeAnglis et al, 1999; Hiramoto et al, 1960). 
Using a yet another novel strategy, Einhaus et al (2004) coated microscopic oil 
droplets containing the anticancer drug docotaxel with fibrinogen for successftilly 
extending the survival of mice bearing the TA3/St mammary tumor that has a fibrin 
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rich microenvironment, from 14.5 to 29.5 days. The authors attributed the extended 
efficacy to the conversion of droplet bound fibrinogen to fibrin by thrombin acting 
locally, facilitating the adherence to tumor cells and retention in the tumor 
environment. 
1.2.2.5.1.6. Release of growth factors 
Extracellular matrix proteins (ECM) and growth factors play a seminal role in cellular 
migration, proliferation as well as formation of various tissues. Fibrin matrices, in 
view of their innate ability to bind to ECM proteins and several growth factors 
therefore continue to remain favorite scaffolds in tissue engineering. Fibrin clots bind 
to platelets through platelet membrane receptor GPIIb-IIIa (Podolnikova et al, 2005), 
that also bind the ECM proteins, Willebrand factor, fibronectin, vitronectin and 
fibrinogen (Charo et al, 1987) and turn into scaffolds for migrating cells and a 
repository for growth factors. Thrombospondin also binds strongly to a and P chains 
of fibrinogen (Bacon-Baguley et al, 1990). 
While some growth factors like bFGF (Sahni et al, 1998) VEGF i65 (Sahni and 
Francis, 2000) bind directly to fibin/fibrinogen, other are associated with the clots 
through heparin. The growth factors that are known to bind to fibrin clots through 
heparin include fibroblast growth factor (bFGF), epidermal growth factor (EGF), 
PDGF (-A, -B) and VEGF 165, acidic and basic fibroblast growth factor (aFGF, bFGF) 
transforming growth factor pi, P2 (TGF pi, P2) neurotrophin-3 (NT-3), brain derived 
neurotrophic factor and nerve growth factor (NGF) (Breen et al, 2009; Ahmed et al, 
2007). Efforts to enhance the binding of several growth factors to fibrin supports 
through heparin enrichment have also been undertaken (Jeon et al, 2005). In a more 
attractive strategy, the heparin binding domain of the growth factor is coupled to 
substrate sequence of a transglutaminase (NQEQVSP) to generate a bifiinctional 
peptide that can in turn be incorporated into the fibrin matrix with the help of 
transglutaminase (Sakiyama et al, 1999). The release of the growth factor thus 
associated with the plasmin scaffold is regulated by the activities of plasmin and 
heparinase. NGF delivered through such heparin binding delivery system was shown 
by Sakiyama-Elbert and Hubbell (2000) to be effective in promoting neurite extension 
of dorsal root ganglia. 
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Studies describing the synthesis of bioactive adhesion domains for incorporation in to 
the fibrin matrix through transglutaminase catalyzed reaction are also available. The 
bidomain peptides investigated include those derived from a2-plasmin inhibitor 
(Schense and Hubbell, 1999), laminin (Schense et al, 2000) VEGF121 (Ehrbar et al, 
2008) and ephrin B2 (Zisch et al., 2004). In an alternative approach the fibrin binding 
kringle domain of plasminogen was fused with bFGF and the fusion product bound to 
fibrin strongly, was released gradually, significantly enhanced neovascularization as 
well as promoted cell proliferation in rats (Zhao et al, 2008). Inclusion of additional 
plasmin degradation domain in the P-NGF sequence fused with the transglutaminase 
substrate was envisaged to facilitate control of growth factor release according to 
cellular demand. The fusion protein was superior in promoting neurite growth than 
the non-modified P-NGF (Sakiyama-Elbert and Hubbell, 2000). 
1.2.2.5.1.7. Liposomes entrapped in fibrin gels 
One promising strategy of slowing down the release of small and large molecules 
from fibrin matrices is their prior entrapment in liposomes, the small lipid vesicles 
typically prepared using naturally occurring lipid molecules. Being biodegradable and 
usually non-immunogenic, liposomes can be tailor-made for specific applications in 
terms of size, charge, permeability, etc. A great body of information on the techniques 
of preparation of liposomes is available (Basu and Basu, 2002). Liposomes are 
usually prepared by sonication of phospholipids in aqueous media or removal of 
detergents from the phopholipid detergent mixtures (Zumbuehl and Weder, 1981). 
The highly attractive feature of liposome as the delivery system of water soluble 
drugs and proteins of pharmacological significance is retention of the entrapped 
substances in the preferred aqueous environment within the vesicles while the 
liposomal membrane protects them from various destabilizing factors. Alternatively, 
lipid soluble molecules may be associated with the liopsomal membranes for a variety 
of applications (Fujisawa et al, 1987). Of the large choice of procedures available for 
liposome preparation, several are quite mild and allow the encapsulation of delicate 
molecules like proteins without affecting their structure and biological activity 
significantly (Weiner, 1994). Some serious efforts have also been made to use 
specially desinged liposome for extending the retention of pharmaceuticals including 
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proteins that otherwise readily diffuse out from the highly porous fibrin gels 
(Senderoffe/a/., 1996). 
Meyenburg et al. (2000) encapsulated a model protein horse radish peroxidase (HRP) 
in liposomes prepared using n-octylglucoside and phosphatidyl choline by the 
controlled detergent release procedure. It was shown that entrapment of the liposomes 
in fibrin resulted in their complete retention and the HRP containing liposomes could 
only be released by the degradation of fibrin matrix. The authors claim that release of 
liposomal material could be further regulated by altering the clot composition and 
inclusion of fibrinolysis inhibitors. Chung et al. (2006) developed a fibrin 
encapsulated liposome in chitosan matrix (FLCM) with a view to extend the release 
duration of the entrapped substances. The influence of surface charge of the 
liposomes and crosslinking of the fibrin network on their retention of the model drug 
quinacrine in the FLCM was investigated. Surface charge of the liposome played a 
significant role and those with neutral surface charge were retained for longer 
duration as compared the liposomes bearing polyethylene glycol on their surface. 
Crosslinking of the FLCM with glutaraldehyde also slowed dovra the release of 
quinacrine up to 17 days with 50 percent reduced initial burst. The release properties 
of a water soluble cardiovascular drug Tirofiban from the FLCM were remarkably 
similar those of quinacrine. A subsequent study from the group (Wang et al, 2008) 
showed that the chitosan-fibrin composites with 50 |um pores were effective in 
retaining the Tirofiban and the release could be further retarded if the composite is 
crosslinked with high concentration of glutaraldehyde. The drug released from the 
composites retained its pharmacological action and inhibited adenosine diphosphatase 
and induced platelet aggregation 
1.2.2.5.1.8. Stabilization of flbrin supports 
The principal problems associated with fibrin gels are shrinkage, high porosity and 
rapid degradability. Also the gels are relatively weak to withstand the dynamic 
physiological events in the in vivo environment. Strategies of stabilization of the 
fibrin matrices to facilitate sustained release of the entrapped pharmaceuticals over a 
long duration have also been examined in considerable detail. These range from 
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simple manipulation of conditions during the preparation of fibrin gels to chemical 
modification and preparation of composite gels. 
1.2.2.5.1.8.1. Manipulation of conditions during preparation of the gels 
Fibrin matrix stability can also be improved to some extent by controlling pH, 
concentration of calcium ions, fibrin and thrombin during the clot formation. Eyrich et 
al. (2007) observed that optimal pH for preparing stable gels lies in the range 6.8-9.0. 
Fibrin gels were stable when the fibrin concentration in the preparation was at least 25 
mg/ml and calcium concentration more than 20 mM (Eyrich et al, 2007). Large 
increases in fibrin concentration however lead to a decrease in average bundle 
thickness while the fibrin gels prepared using low Ca^^ contained fibres with small 
bundle diameters and increase in total number of fibre bundles (Herbert et al, 1998). 
Fibrin microbeads (FMBs) are tiny (50-250 micrometer) highly stable, spherical and 
dense preparations containing heat denatured fibrin crosslinked with factor Ilia 
(Gorodetsky et al, 1999). The FMBs are useful in the isolafion and growth of blood 
(Rivkin et al, 2007) and bone marrow (Kassis et al, 2006), mesenchymal stem cells 
and have potential in gene and cell therapy (Shimony et al, 2006). 
1.2.2.5.1.8.2. Use of composite matrices 
Composite scaffold containing various more stable synthetic and natural polymers 
have been prepared by several workers and used with varying degrees of success. The 
hybrid scaffolds offer the advantage of combining stability, definite size and shape 
offered by the natural or synthetic polymers, while fibrin facilitates cell invasion and 
growth. A number of composite fibrin preparations have been investigated for their in 
vitro, as well as in animal and human studies. These include fibrin composite 
preparations containing polyethylene glycol (Peled et al, 2007), polyurethane (Lee et 
al, 2005), polycaprolactone (Van Lieshout et al, 2006) and P-tricalcium phosphate 
(Weinand et al, 2007). Some composites containing multiple supporting molecules 
have also been used (Eyrich et al, 2007; Weinand et al, 2007). Reports on the 
modification of fibrin/fibrinogen with molecules like PEG (Dikovsky et al, 2006) and 
albumin (Takeoka et al, 2001) are also available. While scaffolds prepared from 
PEG-fibrin were more stable and did not seriously affect the cellular migration, the 
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fibrinogen-albumin polymers were irreversibly attached to the platelet immobilized 
surface through surface GPIIb/IIIa in the reconstituted blood. 
A number of natural polymers in view of their biocompatibility have also been 
employed in the preparation of fibrin composites. Among the more attractive hybrid 
scaffolds used, those prepared using collagen appear most promising. In an interesting 
study Gumming et al. (2004) measure the tensile strength of collagen, fibrin and 
combined collagen and fibrin gels embedded with rat aortic smooth muscle cells. The 
tensile strength of the composite was remarkably higher than that of either pure 
collagen or pure fibrin gels. Fibrin-collagen gels have also been tested as an in vitro 
model of cornea with adjacent sclera (Ahmed et al, 2007). Beneficial effects of 
inclusion of collagen in fibrin gels in graft fixation in cartilage repair in chicken 
model have also been reported (Perka et al, 2000). Fibrin gels containing hyaluronic 
acid facilitate the maintenance of stable phenotype and synthesis of cartilage used 
extracellular matrix in nude mice (Park et al, 2005). Alginic acid containing fibrin 
martrices have been investigated in some detail and shown to promote initial cell 
proliferation and subsequent preservation of differentiated cells facilitating the 
establishment of a stable matrix structure both in vitro (Perka et al, 2000a) and in 
v/vo(Perkae/a/., 2000b). 
Fibrin has also been combined with agarose to prepare a stable corneal model in 
rabbits in which endothelial stromal and epithelial cells were layered sequentially in 
the matrix (Alaminos et al, 2006). Aper et al (2004) reinforced the fibrin gels with 
the polymeric biodegradable polyglactin and co-cultured the endothelial cells and 
myofibroblasts in vitro. While structured co-culture of the cells was obtained, 
inadequate supply of nutrients and oxygen restricted cell growth especially in the 
matrix interior. 
1.2.2.5.1.8.3. Use of inhibitors 
An alternative strategy that is widely used to prolong the in vitro and in vivo stability 
of fibrin scaffolds is the use of inhibitors of plasmin, metallo and other proteinases. 
Proteinic inhibitor like aprotinin which now is a component of several commercial 
glues (Table III) and smaller molecules like tranexamic acid and 8-aminocaproic acid 
have also been shown to slow down the degradation of various fibrin gel preparations. 
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Collagen production and tissue formation by myofibroblats was promoted by 
aprotinin in a concentration dependent manner when incorporated in the fibrin gels 
(Ye et al, 2000). While fibrin gel myofibroblasts structures disappeared in two days 
in absence of aprotinin, maintenance of three dimensional structure and higher 
collagen content and improved tissue development was recorded in samples 
containing the inhibitor. Inclusion of aprotinin has however been shown to interfere 
with tissue formation by inhibiting the regeneration of granulation tissue and was 
shown to be not particularly beneficial during wound healing in rats (Marx and Mou 
2002). Aminocaproic acid, while protecting the fibrin gel integrity did not affect then 
collagen production by the smooth muscle cells favorably (Grassl et al, 2003). The 
inhibitor however decreased ECM formation, presumably by preventing crosslinking 
of collagen molecule by transglutaminase (Mol et al, 2005). 
1.2.2.5.1.8.4. Cross-linking of the fibrin gels 
Crosslinking of the fibrin gels is yet another strategy that has been applied to 
strengthen the fibrin gels. While glutaraldehyde croslinking has been widely 
investigated, some reports suggest that it may be quite toxic (Gough et al, 2002). 
Genipin isolated from Gardenia jasminoides was used successfully by Dare et al 
(2009) to crosslink fibrin scaffolds and induce chondrogenic differentiation of human 
primary articular chondrocytes. Sell et al (2008) crosslinked elctrospun fibrinogen 
scaffolds with three bifuctional regagents glutaraldehyde, l-ethyl-3- (1-3 dimethyl 
aminopropyl) carbodiamide (EDC), and genipin and investigated their peak stress 
modulus and degradation. Both EDC and genipin were effective in enhancing scaffold 
mechanical properties, decreased the degradation in vitro but exhibited some 
recalcitrance to the migration of fibroblasts and the synthesis of collagen in the 
scaffold. Glutaraldehyde crosslinking however proved to be toxic. 
1.2.3. Synthetic Polymers 
A number of synthetic polymers have also been investigated for their drug delivery 
potential. Most of the synthetic polymers used are biologically inert and are 
hydrolytically degradable (Nair and Laurencin, 2007) as the bonds (esters. 
orthoesters, anhydrides, carbonates, amides, urethanes, ureas, etc) present in their 
back bone are prone to spontaneous/enzymatic hydrolysis. They have more 
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predictable properties such as batch-to-batch uniformity and preferred as implants due 
to their minimal site to site and patient to patient variations compared to bio polymers 
(Katti et al, 2002). They also possess unique properties because their release profiles 
can be tailored for specific applications (Nair and Laurencin, 2007). The successful 
performance of the first synthetic poly (glycolic acid) based suture system led to the 
design and development of a new array of synthetic biodegradable polymers as 
transient implants for orthopaedic and other medical applications (Behravesh et al, 
1999; Middleton and Tipton, 2000). This was followed by extensive research by 
several groups of workers for custom designing of biodegradable polymer systems 
with predictable erosion kinetics as drug/gene delivery vehicles or as scaffolds for 
tissue engineering. Some of the more widely used synthetic polymers are discussed 
below in some detail. 
1.2.3.1. Polyphosphazenes 
Polyphosphazenes are polymers made up from the repeated unit of (-RR'P=N-). 
Where the R and R' are usually alkoxy, amino, (R2N), or halogens (such 
as chloride or fluoride) (Allen, 1981). They are a relatively new class of polymers, 
quite distinct from all the biodegradable polymers synthesized so far, due to their 
synthetic flexibility, versatile adaptability and usefulness as short term medical 
implants. A polyphosphazene-doxorubicine hydrogel was used for the local delivery 
of cancer therapeutics (Chun et al, 2009) and endomethicine (Zhang et al, 2009) in 
the arthritic mice. Another study performed by Luten et al (2003) used a cationic 
phosphazene for the delivery of plasmid pCMVLacZ containing bacterial LacZ gene. 
The phosphazenes have also been used with some success for the delivery of proteins 
such as calcitonin (Aldini et al, 2001) and insulin (Caliceti et al, 2000). Eng et al 
(2010) demonstrated that polyphosphazenes have appreciable potential in the in vivo 
delivery of antigens and other immunotherapeutic agents. 
1.2.3.2. Polyurethanes 
The use of biodegradable polyurethane as medical appliance has rapidly become a 
fascinating new field of research in biomedical sciences and tremendous progress has 
been made in this area during the last few year years. Applications of the materials in 
the field of tissue engineering and drug-controlled delivery system have been 
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reviewed (Fu et al, 2003). These materials possess excellent properties such as good 
biocompatibility, mechanical strength, facile formation and are inexpensive (Fu et 
al, 2003) Controlled delivery of drugs is a major issue in the treatment of ocular 
diseases and spectrum of macromolecular structures offered by polyurethanes have 
been used for the delivery dexamethasone acetate in the treatment of uveitis (da Silva 
et al, 2009). A polyurethane containing different fiinctional groups was synthesized 
for the delivery of cefamandole nafate and rifampin (RIF). The drugs were chosen 
mainly because of their broad action spectrum. The in vitro release of antibiotics from 
the polyurethanes was shovm to depends upon antibiotic matrix and antibiotic-
antibiotic interactions the bacterial growth was inhibited up to 23 days (Ruggeri et al, 
2007). Controlled local delivery of chlorhexidine diacetate was also accomplished 
using a polyurethane matrics (Huynh et al, 2010). In yet another study an injectable 
polyurethane scaffold was use for local delivery of tobramycin in the animal models 
that remain biologically active against Staphylococcus aureus (Hafeman et al, 2010). 
1.2.3.3. Polycaprolactones 
Poly(epsilon-caprolactone) (PCL) is a very slowly biodegradable and biocompatible 
polymer investigated as long-term drug delivery system. PCL has been studied for 
extended and controlled intravitreous release of dexamethasone in the rabbit eye 
(Fialho et al, 2008). Quercetin administration is effective in the management of 
arthritis but the bioavailability of quercetin is a matter of concern in such treatments. 
Polycaprolactone microspheres were successfiilly used for the controlled release of 
quercetin in the treatment of rheumatoid arthritis in rabbit and Wistar rats (Natarajan 
et al, 2010). In an earlier study gravity spun caprolactone fibres of diameter 170-220 
microns were prepared and used for the delivery of gentamycin in combating the 
infection associated with musculoskeletal injuries and periodontal disease (Chang et 
al, 2008). Besides, the polycaprolactone in combination with other natural and 
synthetic polymer has been used for the sustained delivery of various small and 
macromolecules. These include caprolactone-collagen for delivery of gentamycine, 
caprolactone-starch for the delivery of BMPs (Balmayor et al, 2009), caprolactone-
polyethylene glycol for the delivery of doxorubicin (Gou et al, 2009) and methoxy 
poly(ethylene glycol)-polycaprolactone (mPEG-PCL) for the delivery of cisplatin 
(LiX e/a/., 2008). 
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1.2.3.4. Poly(ortho esters) (POEs) 
POEs are a class of hydrophobic, surface eroding polymers which are both 
biocompatible and biodegradable. The polymer erosion in aqueous medium is slow 
but the rate of degradation, pH sensitivity, and glass transition temperature can be 
controlled by using diols (Martina et al, 1998). Polyorthoester have been used for the 
local delivery of indomethacin for inhibition of reossification of the bone defects 
(Solheim et al, 1995) as well as in the delivery of insulin like growth factor 1 (Busch 
et al, 1996). Polyorthoester microspheres were also found useful in the delivery of 
DNA vaccine (Nguyen et al, 2008). POEs predominantly undergo surface-confined 
erosion in aqueous environment (Heller et al., 2002), therefore small quantity of 
resulting acid hydrolysis products diffuse away minimizing DNA degradation. Also 
the ortho-ester bonds in the polymer backbone are relatively stable at physiological 
pH, but hydrolyze rapidly (Heller et al, 2002; Schwach-Abbellaoui et al, 1999) at pH 
5. This hydrolytic sensitivity is exploited to enhanced release of DNA inside antigen 
presenting cells (APCs) after internalization of POE microspheres through 
phagocytosis, while minimizing premature DNA release in the interstitial tissue space. 
More recently a composite of a polyorthoester with poly (ethelinimine) was shown to 
be superior in the delivery of DNA vaccine as compared to the earlier used 
polyorthoester (Nguyen et al, 2008). Polyorthoester are designed for frequent ocular 
administration of drugs including dexamethasone and (5-FU) in glaucoma infiltering 
surgery. Dexamethasone shows anti-fibroblastic properties while 5-fluorouracil is 
anti-inflammatory in nature (Zignani et al, 2000). A more effective preparation of 
Polyorthoesters was prepared by combining them with PLGA and used with 
reasonable success in the delivery of both water soluble BSA and water insoluble 
cyclosporin (Shi et al, 2003). 
1.2.3.5. Poly(D,L- Lactic-co-Glycolic acid) (PLGA) Polymers 
PLGA is a polyester composed of one or more of three different hydroxy acid 
monomers, D-lactic, L-lactic, and/or glycolic acids. The polymers can be readily 
prepared both in the form of highly crystalline [e.g., poly [(L-lactic acid)], or 
completely amorphous [e.g. poly(D,L-lactic-co-glycolic acid) material. PLGA can be 
produced as spherically shaped polymeric matrix ranging in diameter from 1 to 250 
^m and has been widely explored as a controlled delivery system both for native and 
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synthetic peptides, proteins and more recently, nucleic acids in immunological studies 
(Eldridge et al, 1993; O'Hagan et al, 1993). 
1.2.3.5.1. Preparation of PLGA microspheres 
A number of procedures are available for the preparation of biodegradable PLGA 
microspheres. The properties of microspheres are determined by the preparation 
strategy therefore, the procedure should be carefully selected to obtain microspheres 
of desired properties. It is desirable that the procedure of choice should give good 
yield of the microspheres, good entrapment yield, not cause inactivation of the 
entrapped material, and offer adjustable release profile and low bust effects. Spray 
drying, double emulsion and phase separation strategies are commonly used in the 
preparation PLGA microspheres. 
Spray drying is a simple, rapid, reproducible and easy to scale-up technique (Masters, 
1991). It is a one stage process necessitating mild temperature conditions (Pavanetto 
et al, 1993) and is less dependent on the solubility of the drug (e.g. hydro solubility) 
and the polymer (Bodmeier and Chen, 1988). In this procedure the drug to be 
entrapped in the solid form is dispersed in polymer dissolved in appropriate organic 
solvent by high speed homogenization, and this dispersion is atomized in a stream of 
heated air. Droplets of PLGA are formed as the solvent evaporates. Typical size of 
the microspheres thus formed ranges from 1 to 100 [am, depending upon atomizing 
conditions. The microspheres are collected from air stream by a cyclone separator. 
Residual solvent is removed by vacuum drying. Nitrogen atmosphere is technically 
feasible in spray drying. The advantages of the procedure include possibility of 
control of microsphere size, reproducibility, reasonable control of release profile of 
entrapped drug and tolerance to small changes of polymer specifications. Chance of 
aggregation and denaturation of sensitive protein during the entrapment procedure 
however, exist. 
In the double emulsion procedure, protein or the drug to be entrapped in aqueous 
solvent is emulsified with a non-miscible organic solution of the polymer to form 
water in oil emulsion (Hora et al, 1990; Cohen et al, 1991). The organic solvent used 
mostly is dichloromethane (DCM) because of its high solvation capacity for PLA and 
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PLGA polymers (Youan, 2004), low boiling point of (40°C) and being one of the least 
toxic of the halogenated solvents (Blanco et al, 2005). The emulsion formed is then 
rapidly transferred to an excess of an aqueous medium, containing a stabilizer 
(usually polyvinyl alcohol) (Baras et al, 2000), homogenized or vigorously stirred to 
initially form a double emulsion of water in oil in water. Subsequent removal of 
organic solvent by heat, vacuum or both results in phase separation of polymer and 
core to produce microspheres. Instead of solvent evaporation, solvent extraction can 
also be undertaken yielding microspheres containing protein. The main advantage of 
this procedure is the high encapsulation yields achievable, while difficulty in 
regulating the release profile of the microsphere is the major drawback (Sinha and 
Trehan, 2003). 
In phase separation techniques polymer and dichloromethane are taken in solution in 
which proteins/drugs are dispersed in solid form. Silicon oil is added to this dispersion 
at a defined rate, reducing solubility of polymer in its solvent. The polymer-rich liquid 
phase (coacervate) entrappes the dispersed drug particles and the 'embryonic' 
microspheres are subjected to hardening and washing step using heptanes. The 
process is quite sensitive to polymer properties, residual solvents is also an important 
issue (Sinha and Trehan, 2003). 
1.2.3.5.2. Kinetics of degradation of PLGA microsphere 
The release kinetics of entrapped protein/pharmaceutical from the PLGA 
microspheres may be homogeneous or heterogeneous depending upon the nature of 
degradation of the polymer. In homogeneous type of degradation, bulk erosion occurs 
in which initial random cleavage of hydrogen bonds due to hydration is followed by 
cleavage of covalent bonds. The molecular weight decreases continuously due to 
cleavage and solubilization of the low molecular weight fi-agments and complete 
absorption. PLGA in this case retains its original shape and mass until significant 
degradation has occurred (over 90%). Heterogeneous degradation is only confined to 
the surface of the polymeric carrier where it is interfaced with the physiological 
environment. The degradation rate is constant and the undegraded carrier retains its 
chemical integrity during the process. The lactic and glycolic acids, produced by the 
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degradation of PLGA can be readily oxidized via Kreb's cycle (Waeckerle-Men and 
Groettrup, 2005). 
1.2.3.5.3. Interaction of microsphere associated proteins with immune system 
Protein depots are formed by the microspheres at the site of injection, from which 
proteins are slowly released. Design of the microspheres is an important parameter; 
those of sizes smaller than 10 |im were demonstrated to have adjuvant activity via 
their uptake by macrophages and dendritic cells (DCs), and their localization in lymph 
nodes (Singh and O'Hagan, 1999), and to induce CTL responses (Maloy et al, 1994; 
Moore et al, 1995; Nixon et al, 1996; Partidos et al, 1997; Men et al., 1997). On the 
other hand, large sized microspheres (>10 |j,m) undergo biodegradation (Eldridge et 
al, 1993; O'Hagan et al, 1993) before phagocytosis occurs. One or several layers of 
macrophages cover the microsphere as wound healing response at the site of injection 
(O'Hagan, 1996; Beier and Gebert, 1998). Consequently degradation, release of 
antigen, location and antigen presentation from the microspheres larger than 10 ^m 
are expected to be different from those of the smaller size. A foreign body response 
occurs, upon injection of the microspheres, resulting in an acute initial inflammation. 
This initial inflammation is followed by the infiltration of small foreign body giant 
cells and neutrophils and the immune cells present at the site take up the released 
antigen causing an immune response. It is essential to facilitate the release of protein 
in its native conformation since the release of aggregated or denatured protein from 
the microspheres may result in an unwanted immune response (Cleland et al, 1993). 
1.2.3.5.4. Delivery of vaccines/antigens 
These PLGA microspheres have been widely investigated for their ability to entrap 
various proteins/vaccines for generating immune response. Group B Streptococcus 
(GBS) is the leading cause of bacterial neonatal sepsis and meningitis. The GBS has a 
capsular polysaccharide (CPS) and is the major target of antibody mediated immunity. 
It was encapsulated in PLGA microsphere along with immuno stimulatory synthetic 
guanosine (CpG) as a potent adjuvant. Mice immunized with the PLGA 
microparticles containing the GBS type III polysaccharide and CpG adjuvant 
(PLGA/GBS/CpG) responded by producing remarkably higher anti-GBS antibody 
response as compared to the animals receiving the non-encapsulated GBS 
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polysaccharide antigen or those given PLGA encapsulated GBS polysaccharide 
without the addition of the CpG (Sinha and Trehan, 2003). 
Tetanus is a major health problem in the developing and under- developed countries, 
with approximately one million new cases occurring each year. Tetanus is an 
intoxication manifested primarily by neuromuscular dysfunction and vaccination is a 
useful appropriate strategy to prevent this disease. Tetnus toxoid (TT) was entrapped 
in PLGA with different molar ratio of lactide to glycolide (50:50, 75:25) and integrity 
of antigen was evaluated during in vitro release (Boehm et al, 2002). Al adsorbed TT 
is used for in vivo induction of tetanus-specific antibodies (Jung et al, 2002). TT 
microspheres elicited antibody titres as high as conventional Al adsorbed toxin which 
lasted for 29 weeks. The study indicated that tetanus toxoid microspheres can act as a 
potential vaccine candidate without the need of boosters (Boehm et al, 2002). 
Japanese encephalitis (JE) is a mosquito bom viral disease wide spread in humans 
mainly in Asian countries. It affects the central nervous system, causing severe 
complications and even death and vaccination is one of the important strategies of 
protection against the disease. JEV {Japanese encephalitis virus) vaccine was 
encapsulated both in porous and less porous PLGA microspheres but the rate of 
release was faster in the former as compared to the later. The study suggested that 
PLGA micro spheres have potential as carriers of oral vaccines or through Peyers 
patches across gastro intestinal tract (GIT) (Khang et al, 1999). 
Diphtheria is a communicable disease caused by Corynebacterium diphtheriae which 
colonizes and forms a pseudo membrane at the infection site. Diphtheria toxin (DT) 
produced by the pathogen is responsible for the typical systemic toxemia. DT is used 
for active immunization against diphtheria. Formulations were prepared that contain 
relatively hydrophilic PLGA in a ratio of 50:50 (lactide to glycolide ratio) with 
entrapped alum adjuvantand the DT. Immunization of the guinea pig with the 
preparation lead to the generation sustained and high titre of specific antibody against 
the toxin suggesting that microsphere vaccines may be highly effective after single 
immunization (Johansen et al, 1999). 
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Cholera is an acute intestinal infection caused by the bacterium Vibrio cholera, that 
produces an enterotoxin causing copious, painless, watery diarrhoea and quickly lead 
to severe dehydration and death if treatment is not promptly given. Vaccination is 
widely used for the prevention of cholera. Vibrio cholera (VC) cells was successfully 
entrapped in the poly(D,L-lactide-co-gly colide) microspheres by double emulsion 
method with trapping efficiencies up to 98% and the immnunogenic potential of VC-
loaded microspheres investigated. VC loaded microsphere physical mixed with ampB, 
sham microsphere and VC in PBS was given in the mice orally. Results indicated that 
on oral administration VC-loaded microspheres and VC loaded microsphere 
physically mixed with amphotericin B evoke vibrio-specific serum IgG and IgM 
responses as well as vibriocidal antibody activity in mice (Yeh, 2002). 
1.2.3.5.5. Delivery of other proteins 
The PLGA microspheres have been used for the delivery of a number of other 
proteins, hormones and enzymes for a variety of applications other than as vaccines 
candidates. Deficiency of prolidase results in chronic intractable ulcerations of the 
skin particularly of lower limbs because it has a role in final stages of protein 
catabolism. To obviate the problem, the enzyme was entrapped in PLGA 
microspheres by water/oil/water (w/o/w) multiple emulsion technique and the stability 
of enzyme studied both in vitro and in vivo. The enzyme entrapped inside the PLGA 
microspheres was highly stable both in vitro and in vivo and that released from the 
microspheres was active suggesting the possibility of using the microspheres in 
enzyme replacement therapy through microencapsulation (Genta et al, 2001). 
Interferon aaa (IFN a2a) is used in the treatment of chronic hepatitis C in adults. To 
improve the stability and loading efficiency of the interferon a new microsphere 
delivery system comprising calcium alginate cores surrounded by PELA (poly D,L-
lactide-poly (ethylene glycol) has been used (Zhou et al, 2002). Core-coated 
microspheres stabilized the IFN a2a in the PELA matrix and indicated high 
encapsulation efficiency and biological retention as compared to conventional 
microspheres. The extent of burst release was only 14% in core-coated microspheres 
as against 31% observed in the conventional microspheres. 
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Several newborns are prone to allergies against milk proteins and the allergic reaction 
can be prevented in the newborns by inducing oral tolerance to the proteins. The 
major allergenic milk protein |3-lactoglobulin(BLG) was entrapped in the PLGA 
microspheres and administered orally. The microsphere formulations significantly 
reduced the amount of protein required to lower specific anti BLG IgE response, 
suggesting that microsphere entrapment may be an optimal means of inducing oral 
tolerance (Fattal et al., 2002). 
Insulin is the most important regulatory hormone in the control of glucose 
homeostasis. More than 50 million people around the world require daily parenteral 
injections of insulin to stay healthy and live normally (Chien, 1996). A controlled 
release system for long-term therapy of this disease that can obviate the need for 
repeated painful injections in the diabetes patients. Insulin was encapsulated in blends 
of poly(ethylene glycol) with PLA homopolymer and FLO copolymer using w/o/w in 
the double emulsion method (Yeh, 2000). Insulin-loaded micro spheres were capable 
of controlled release of insulin for 28 days with in vitro delivery rates of 0.94 and 0.65 
Hg insulin /mg particle/ day in the first 4 days and steady release with rate of 0.4 and 
0.43 ng insulin/mg particle / day over the following 4 weeks respectively. 
1.3. Candidiasis 
The genus Candida comprises over 150 species that includes some pathogenic forms 
like the Candida albicans. The term Candidiasis encompasses a spectrum of 
infections, ranging from superficial mucosal infections to life-threatening invasive 
afflictions involving virtually every organ of the body. The incidence of candidiasis 
has paralleled the use of modem medical strategies that adversely affect the immune 
system, suggesting the vulnerability of the immunocompromised. While cutaneous 
and mucocutaneous infections caused by C. albicans are relatively common, the 
morbidity and mortality of systemic candidal infections has increased significantly 
over the past two decades (Hajjeh et al., 2004; Pfaller et al., 2004; Gudlaugsson et al., 
2003; Lin et al., 2001). Increase in the proportion of disseminated candidiasis appears 
to be directly associated v^th use of intravascular catheters, broad-spectrum 
antibiotics, surgical procedures, prolonged ICU stay, and immunocompromising 
conditions of host, etc. (Hajjeh et al., 2004; Richardson et al., 2005; Clark and Hajjeh 
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2002). While anti-fungal drugs including polyenes like amphotericin B and azoles 
like fluconazole and itraconazole have been useful both in prevention and treatment of 
candidiasis, reports several non-albicans species such as C krusei, C. glahrata, C. 
tropicalis and C lusitaniae, with higher resistance to anti-fungal drugs are also 
available (Krcmery and Barnes, 2002; Pfaller et al, 2003). 
1.3.1 Dichotomist relationship with the Host: Commensal and Pathogen 
Candida albicans is saprophytic in humans, residing mainly in the gastrointestinal 
(GI) tract, vulvovaginal tract or oropharyngeal cavity. Acquisition of C. albicans 
infection may occur during child birth as the neonates emerge out from the protective 
enviroimient of the placenta. Subsequently transmission of the fungus could also 
occur through human contact. Apparently, the ill developed immune system of the 
neonates allows the establishment of C. albicans as a member of the normal micro 
flora. However, the presence and stability of fungal colonization may be both 
transitory and variable (Harmula et al, 1999; Cohen et al, 1969). A number of factors 
including weakened immunity, physiology, or normal micro flora influence the 
establishment and maintenance of C. albicans in the GI tract and other host sites. 
Investigations that provide further insight into the above observations are clearly 
required to determine the commensal relationship between the fungus and the native 
system of the host. It is not surprising therefore that the immunocompromised patients 
are the most vulnerable to Candida infection. 
Infections Surveillance (NNIS) system was established to monitor the incidence and 
prevalence of various nosocomial diseases that include the potential life threatening 
candidiasis. The survey indicated that the blood stream and urinary tract are most 
commonly associated sites with Candida-related nosocomial infections (Jarvis and 
Martone, 1992; Richards et al, 1998; Richards et al, 1999). Among the hospitals 
conducting NNIS surveys of medical intensive care units, Candida species accoimted 
for the most common pathogens of nosocomial urinary tract infections between 1986 
and 1990 and again between 1992 to 1997 (Jarvis and Martone, 1992; Richards et al, 
1999). Urinary catheters were associated with 95% of the urinary tract Candida 
infections (Richards et al, 1999). Although most urinary tract infections are not life-
threatening, treatment of asymptomatic candiduria patients would be beneficial to 
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those who have undergone renal transplantation, have had neutropenia or have 
undergone invasive urologic procedure (Mochon and Cutler, 2005). 
1.3.2. Disease Incidence 
The increasingly common incidence, prevalence, and potential severity of candidiasis 
argues strongly in favor of vaccine development. In the year 1970, National 
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Fig.1.5 Taxonomic classification of Candida and its phylogenetic relation to other 
yeast species. 
Furthermore, it was shown that asymptomatic candiduria is indicative of high 
mortality rate (20-25%) in elderly and incapacitated patients (Lundstrom and Sobel, 
2001). Data collected by the Surveillance and Control of Pathogens of Epidemiologic 
Importance (SCOPE) between 1995 and 1996 shows that Candida species were the 
fourth most common cause of nosocomial bloodstream infections, that constitute a 
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significant 8% of all the infections (Pfaller et al, 1998).The concurrent or recent 
antibiotic therapy (95% of patients), presence of a central venous line (93% of 
patients), and immunosuppression (88% of patients) are the main risk factors 
associated with the Candida bloodstream infection. Death occurred in 52 % of the 
patients with candidemia and mortality directly associated to Candida species could 
be established in 23% of the patients (Karlowsky et al, 1997). 
In healthy individuals the oral carriage of yeast averages between 2.0 and 71.3% 
(Odds, 1988). These endogenous yeast can appear as oral candidiasis but is often 
influenced by local and systemic factors when the hosts are incapacitated. Numerous 
local factors that are associated with oral candidiasis such as dentures, impaired 
salivary gland function, inhaled steroids and oral cancer. Other contributing factors 
include old age, smoking, diabetes mellitus, Cushing's syndrome, 
immunosuppression, malignancies, nutritional deficiencies and broad spectrum 
antibiotics (Akpan and Morgan, 2002). Local and systemic factors causing 
mucocutaneous disease are evident in a study of aged who used full upper dentures; 
over 65% developed mucocutaneous disease of the buccal cavity (Dreizen, 1984). 
Immunosuppression was found to be the principal systemic factors among HIV 
positive men whose CD4 count was less than 200/}il; 48.9% of these men developed 
oral candidiasis (Sangeorzan et al, 1994). Vulvovaginitis is the most prevalant form 
of mucocutaneous Candidiasis in woman and approximately two-thirds of all fertile 
women are predicted to experience at least one episode of candidal vaginitis during 
their life time, and approximately 5% may develop frequent recurrent episodes (Odds, 
1988; Giraldo et al, 2000). Also, women with a history of recurrent virginitis have a 
greater tendency for carrying asymptomatic vaginal Candida species than women with 
no history of vulvovaginal candidiasis (Sobel et al, 1992; Giraldo et al, 2000). Many 
clinicians have observed that vulvovaginal candidiasis does not occur at a higher rate 
in HIV-infected women, while persistent mucosal colonization is more common in 
HIV-seropostive women than in healthy individuals. Furthermore, increasing HIV 
loads correlated with persistent vaginal candidiasis rather than incident candidal 
vaginitis (Ohmit et al, 2003). The rising occurrence of both disseminated and 
mucocutaneous candidiasis clearly warrants necessitates clever and effective 
therapeutic approaches against the pathogen. 
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1.3.3. Mucocutaneous and dissiminated Candidiasis 
The prevalent species that causes candidal infections is C. albicans, but it is 
speculated that the liberal use of azole group of antifungal is one of the major reason 
for the increase of incidences of infection by azole resistant species, such as C. 
glabrata, C. tropicalis, C. krusei, C. dubliniensis, and a few others (Boschman et al, 
1998; Milan et al, 1998). In spite of the recent increase in the incidence of non-
albicans infections, majority of the studies directed towards the Candida-host research 
and vaccine development have focussed on C. albicans, because of the leading role 
the species plays in candidiasis. Another major advantage is that the availability of 
animal models (Rabbit, Guinea pig and mice) for candidiasis caused by C. albicans 
(Beck-Sague and Jarvis, 1993; Pfaller et al, 1998; Pfaller et al, 1998; Sullivan et al, 
1997). Both the yeast as well as filamentous form of fungus are responsible for the 
invasions in clinical and experimental candidiasis caused by C. albicans (Odds, 
1988). On the other hand, commensal C. albicans has been correlated with the yeast 
form (Odds, 1988). This finding has put up an interesting question mark on the 
importance of association between filamentation and virulence (Lo et al, 1997; 
Mitchell, 1998). Some non-filamentous species of Candida however, are indeed 
capable of causing disease (Fidel et al, 1999) and it has been suggested that an 
immune response against the yeast form of C. albicans is sufficient for host resistance 
against disease. Candidiasis expresses itself primarily either as cutaneous 
/mucocutaneous form or hematogenously disseminated disease. Cutaneous 
/mucocutaneous candidiasis is clinically and historically as referred as thrush. It 
involves the mucosa of the oral cavity or vaginal tract and may be severe and 
persistent. Mucocutaneous candidiasis is mostly of endogenous origin (Cole et al, 
1996) as verified in a study on cancer patients with severe myelosuppression, in 
whom the occurrence of oropharyngeal candidiasis was almost three-fold higher in 
those colonized with C. albicans as compared to those who did not have any infection 
(Bodey, 1986). The clinical features of oropharyngeal Candida infection include 
stomatitis, angular cheilitis, and oral leukoplakias, where as, in vulvovaginal 
candidiasis pruritis, vulval erythema with or without discharge is commonly 
observed. In individuals with severe T-cell deficiency, including Swiss-type 
agammaglobulinemia or SCID, DiGeorge Syndrome and neoplasms such as thymoma 
(Aronson and Soltoni, 1976), an intractable and progressive chronic form of disease 
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may develop, which often involves extensive areas of the glabrous skin and mucosal 
surfaces, such a condition referred to as chronic mucocutaneous candidiasis or CMC. 
Although mucocutaneous disease may significantly compromise the well-being of the 
afflicted individual, such as HIV/AIDS patients with esophageal candidiasis (Dreizen, 
1984), in case women with chronic or recurring vulvovaginitis (Foxman et al, 2000) 
and CMC patients, mucocutaneous disease is not considered directly life-threatening 
(Dreizen, 1984). Deep organ systems are however associated in case of 
hematogeneously disseminated candidiasis. These include spleen, kidney, heart, liver, 
lung, and may even extend to the central nervous system. Transmission modes include 
persorption from the GI tract and translocation from developing biofilms on 
indwelling catheters (Bodey, 1986). Clinical features include chills and fevers that do 
not respond to bacterial therapy. This form of disease is often life-threatening, even 
when treated with antiftingals. 
1.3.4. Immunity against C Albicans 
The pathogenic dichotomy of disseminated and mucocutaneous form of candidiasis 
has led to very simple immunological explanation. For the prevention of 
mucocutaneous candidiasis, T-cell immunity is required, while neutrophil Sanction is 
necessary for the prevention of disseminated disease. These observations were made 
by the Kirkpatrick et al. (1971) on the basis of his studies on patients with CMC. 
Successive observations following the clinical attempts for immunological repair of 
CMC patients fiarther substantiated and upheld the conclusions regarding some 
relationship between T-cell defects and CMC (Buckley et al, 1968; Hoh et al, 1996). 
The observations shows that neutophil ftinctiong is needed for the prevention of 
disseminated disease and T-cell immunity is essential for protection against 
mucocutaneous Candidiasis. These studies were limited however to patients with rare 
anomaly of thymic aplasia that exhausts and washes out all T cell population but led 
to the prediction that CMC could be induced in mice with congenital thymic aplasia 
(e.g. nu/nu mutant mice). The mice however not only resisted attempts to induce 
mucosal disease, but some even exhibited enhanced resistance to disseminated 
candidiasis (Cutler, 1976; Jones-Carson et al, 2000). Apparently T cells are 
responsible for host defense against mucosal candidiasis but bouts of the vaginal 
candidiasis apparent in woman with normal thymic ftinctions suggests the 
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involvement of non-T cell factors (Tabeta et al, 1984). Unfortunately, mucosal 
candidiasis models with any level of severity are not very satisfactory and this 
complicates attempts to sort out immunological defects that are subtler than those of 
patients with CMC. The story is further complicated by experimental studies in mice 
that demonstrate that THl-dependent cell mediated immunity is critical to host 
defense against disseminated candidiasis (Romani et al, 1995; Bistoni et al, 1993; 
Rogers et al, 1976; Ashman et al, 1999). Mice like humans, are highly susceptible to 
life-threatening disease when rendered neutropenic (Martino et al, 1989). The host 
defense against hematogenously disseminated candidiasis is thus quite intricate and 
incumbent upon a number of diverse factors (Bodey, 1986; Nasser et al, 1997; Bross 
etal, \9S9;Wey etal, 1989; MacDonaldera/., 1998). 
1,3.5 Treatment and Prevention 
Current antifungal treatment for candidiasis comprises a limited armamentarium 
mainly of a small number of strategies relying on the differences between the 
eukaryotic fungal and mammalian cells. The last two decades have however 
witnessed the emergence of several effective strategies in the treatment of fungal 
infections. These include use of amphotericin B formulations (Lopez-Berestein et 
al, 1989), which target membrane ergosterol and create membrane spanning 
channels, several azole derivatives with a broad spectrum of diverse activities such as 
fluconazole, itraconazole, voriconazole, posaconazole and allylamines (terbinafme) 
which target enzymatic synthesis of ergosterol (Ruhnke et al, 1997; Sanati et al, 
1997; Hazen et al, 2003), the cell wall inhibitors echinocandins that include 
caspoflingin, micafungin, which interfere with synthesis of the cell wall 
polysaccharide, P-1, 3-glucan and flucytosine, an anti-metabolite of DNA and RNA 
synthesis (Anderson, 2005). Unfortunately, success rates for many mycoses remain 
unacceptably low and drug therapy against candiadiasis is often limited by high cost, 
toxicity and resistance of the fungus to the drugs (Richardson, 2005). Invasive 
candidiasis is often fatal because of the diagnostic challenges (Bodey, 1986), drug 
resistance (Sangeorzan et al, 1994; Odds, 1988; Johnson and Wamock, 1995), and/or 
a poor immunologic status (Meunier et al, 1992). Patients with mucocutaneous 
disease may either not respond to the over the counter antifungals (White et al, 2001; 
Sharm and Wilson, 2003) or develop recurrent disease as noted above. 
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Prevention of candidiasis, is more manageable, especially with patients undergoing 
invasive medical procedures that place them at high risk of developing the disease. It 
is now a common practice to give such patients antifungal treatment to accomplish a 
reduction of normal C. albicans flora (Kojic, 2004; Comely et al, 2003). The 
importance of preventing certain forms of candidiasis was further recognized when 
weekly fluconazole therapy was successful in reducing the incidence of recurring 
vulvovaginal candidiasis in women (Comely et al., 2003). 
1.3.6. Vaccine against Candidiasis 
The concept of fungal vaccination as discussed above for humans is sound and 
apparently feasible but has not attracted remarkable attention in the past because of 
the relatively low incidence of the infections and the limited geographic distribution 
of several fiingi as compared to many viral and bacterial diseases. However, the 
advent of AIDS and the increasing use of potent immunosuppressive therapies to 
combat autoimmune diseases, malignancies, and transplantation rejection have re-
energized interest in the search for effective vaccines against clinically important 
fungi. Fungal diseases are no longer merely considered mysterious infections but 
recognized as important causes of morbidity and mortality. 
Ideally a vaccine should induce a long-term adaptive immune response and avert the 
invasion or multiplication of its target pathogen without causing significant adverse 
effect to the host (Ada, 1991). The efficacy of the immunoprotection invoked by a 
vaccine depends on nature of the infecting microbe and the host's 
immunocompetence. The aspect of immunoprotection is a major concern when one 
considers the range of candidal infections (i.e. mucocutaneous to disseminated) in 
humans that necessitate both innate and adaptive immunity for effective protection 
(Mochon and cutler, 2005). Unfortunately in case of the immunocompromised 
patients who are most vulnerable to mucocutaneous and disseminated candidiasis, 
induction of active immunity is precluded. Passive immunity therefore appears the 
most beneficial form of immunotherapy in such patients as it provides immediate 
protection to the individual, albeit temporarily. On the contrary, active immunization 
benefits mostly those peoples which are immunocompetent but are at highly 
vulnerable to candidiasis. Women are the major at-risk population for candidiasis and 
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they are the best targets for vaccination. The cells of immune system involved in 
providing protection against candidal vaginitis, particularly recurrent vulvovaginits, 
have not yet been identified. However, an effective immunoprophylatic vaccine could 
potentially prevent the occurrence of vulvovaginal candidiasis, as well as the transfer 
and subsequent colonization of Candida species to new bom infants (Mochon and 
cutler, 2005). Others who should benefit from active immunization are diabetics, 
denture wearers, patients with predisposing iatrogenic factors (indwelling catheters, 
corticosteroid treatment, broad-spectrum or multiple narrow-spectrum antimicrobial 
chemotherapy) and hospital workers (i.e. nosocomial derived infections) (Huang et 
al, 1998). Irrespective of whether immunoprotection against Candida is mediated by 
active or passive immunity, availability of effective immunoprotective agent is the 
need of the hour to in view of the proliferation of the 'at-risk' population. 
Vaccine development against any infectious disease is highly challenging and 
necessitates both scientific and practical considerations prior to taking up the 
endeavor (Hilleman et al., 2002; Milstein and Lambert, 2002). Therefore, following is 
the rationale for initial considerations. There exist strong arguments in favor of 
vaccine development against Candida. These include (i) The disease causes sufficient 
morbidity and/or mortality to be considered a significant public health problem, (ii) 
Currently available disease treatment and prevention measures are inadequate, (iii) 
The normal history of the disease indicates that specific acquired immunity can either 
prevent or significantly reduce the disease severity, (iv) The etiology of the disease is 
limited to one or a small number of closely related agents, all or most of which can be 
affected by an appropriate vaccine formulation. 
Understanding of the mechanisms of protection against hematogenously disseminated 
candidiasis continues to be limited, but new and useful information is surfacing. From 
clinical observations, it is clear that neutropenia is a significant risk factor (Hazen et 
al, 2003; Naider et al, 1983; Denning, 2003) and experimental studies on animal 
models of disseminated candidiasis support this conclusion (Johnson and Wamock, 
1995; Odds, 1993; White et al, 2001; Meunier et al, 1992; Shann and Wilson, 2003; 
Kojic, 2004; Comely et al, 2005). Whereas T-cell deficiency or dysfiinction is not an 
obvious risk factor in humans (Farah et al, 2000), animal models of disseminated 
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disease suggest that T-cell dependent cell-mediated immunity contributes remarkably 
towards host defense against this form of candidiasis (Myers et al, 2003; Fidel et ai, 
2004). Although the results obtained from mouse models may help in the 
understanding of the protective mechanism that is critical to C. albicans defense in 
this species, extrapolating the conclusions to humans may be misleading or 
overstated. To date no correlation has been established between the development of 
disseminated candidiasis in humans and moderate or severe T-cell deficiency in 
HIV/AIDS and CMC, respectively (Nucci et al., 1997; Nasser et al., 1997). Whether 
cell-mediated immunity against disseminated disease is an important factor in humans 
is, therefore, not known; clearly, humans have other mechanisms of handling this 
form of disease. Innate and acquired specific immunity acting in concert or 
independently, could well include phagocytic cells, cell mediated immune responses, 
specific antibodies and a range of associated humoral factors such as complement and 
cytokines (Casadeval et al., 1995). Furthermore, any host defense element that 
prevents unrestrained fungal replication should be sufficient to ward off life-
threatening invasion of the deep organ systems and morbidity associated with 
mucosal tissue disease. 
1.3.7. Vaccination Strategies 
In order to develop an effective Candida vaccine, the complex dichotomy (i.e. 
commensal and opportunistic pathogen) of C. albicans and its interactions with 
human host needs to be understood thoroughly. There are two divergent postulates 
that explain fungus-host interaction. The first is based on the idea that C. albicans is 
present in the host as a latent pathogen controlled by the immune system. When the 
condition of the host becomes devastating this obvious pathogen causes the 
mucocutaneous and disseminated disease. This idea comes from the transitory 
occurrence of colonization by C. albicans in the healthy individuals (Hannula et al., 
1999; Cohen et al., 1969) and the increased predisposition of the development of 
candidiasis in the individual who are colonized prior to immunosuppressive therapy. 
In contrast, the second postulate state that the C albicans-host interaction is a 
mutualistic relationship where both microbe and host derive reciprocal benefits from 
each other. When the condition of the host becomes debilitated, the interaction shifted 
from favorable to invasive state. Accordingly there are two distinctive approaches in 
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the development of a vaccine against candidiasis. One approach involves the complete 
elimination of the organism from the human system (i.e. immunoprophylaxis) 
supporting the theory that Candida species are pathogens. The other involves inducing 
and maintaining an immune response against restricted antigens that correlate with an 
infectious disease state (i.e. immunotherapy), thus permitting the maintenance of the 
mutualistic Candida-host interaction (Mochon and cutler, 2005). 
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cMateriab and ^Methods 
2.1. MATERIALS 
2.1.1. Chemicais 
Tetracycline, daunorubicin, Blue Dextran, Horse Radish Peroxidase (HRP), aprotinin, 
egg phosphatidylcholine, cholesterol, invertase, ortho-phenyl di-amine, 
glutaraldehyde, di-nitro salicylic acid, pig transglutaminase, trypsin, chymotrypsin, 
bicinchonic acid (BCA) total protein determination kit, Freund's adjuvant complete. 
Incomplete Freund's adjuvants and various antibodies used in the study were 
purchased from Sigma Chemical Company (St. Louis, USA). IL-4 and IFN-y cytokine 
kits were procured from BD Biosciences, USA. Monoclonal anti-mouse CD4, CDS, 
CD80 and CD86 their isotypic control were from eBiosciences (San Diego, CA, 
USA). Poly vinyl alcohol (PVA), dichloro methane (DCM), Ethylene diamine 
tetraacetic acid (EDTA), D-Glucose and calcium chloride were procured from Sisco 
Research Laboratory, India. Yeast extract, bacteriological peptone, phenyl methyl 
sulfonyl fluoride (PMSF) and agarose were procured from Hi-Media laboratories 
(Bombay, India). Acetonitrile and HPLC water were purchased from Merck, India. 
Commercially available Fungicin® (Amphotericin B, AmpB) and cefotaxime were 
procured from local medical store. Other chemicals used in the study were of 
analytical grade and procured locally. 
2.1.2. Animals 
Inbred female Balb/c mice (8—10 weeks old), weighing 20±2 gm were obtained from 
the animal house facility of Central Drug Research Institute, Lucknow. Female 8-10 
week old Swiss albino mice of weighing 20±2 gm and 8-10 weeks of age were 
procured from Laboratory Animal Resources, Indian Veterinary Research Institute, 
Barielly, India. Rabbits used in the study were out bred and purchased from a local 
animal supplier. All the animals were provided with plenty of water and diet 
(Hindustan Lever Ltd, India) throughout the investigation, unless mentioned 
otherwise. Bleeding, injection and sacrifice of animals were strictly performed 
following the mandates approved by the Institutional Animal Ethics Committee 
constituted as per the recommendations of Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA), Government of India. 
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2.2. METHODS 
2.2.1. Bleeding of Animals and Isolation of Plasma/Serum 
Rabbit blood was collected from the ear vein with help of a syringe. Nine volumes of 
blood were collected in tubes containing one volume of 72.5 mM EDTA in 0.15 M 
NaCl, mixed and centrifiiged at 416 x g for 10 minutes. The plasma obtained thus was 
collected by aspiration and used immediately or stored at -20 °C till use. Mice were 
bled through retro-orbital puncture with a glass capillary and blood collected in sterile 
Eppendorf tubes. For collection of serum, blood was incubated at room temperature 
for an hour and subsequently kept at 4 °C for retraction of the clot. Finally, the tubes 
were centrifiiged at 2460 x g for 10 minutes at 4 °C and serum collected by aspiration 
and stored if required at -20 °C. 
2.2.2. Evaluation of Clotting Time of Plasma 
In order to determine the optimal conditions, 125 |^ 1 plasma was transferred to the 96 
welled microtitre plates, mixed with 15 |al of appropriate concentrations of CaCh 
solutions in distilled water to give a final concentrations of 4, 8, 16, 24, 32, 40, 48, 56, 
64 and 72 mM calcium respectively. The plates were incubated at 37°C and after 
various time intervals turbidity of the samples was measured at 595 nm (Bale and 
Mosher, 1986) in an ELISA Reader. 
2.2.3. Preparation of Plasma Beads 
Two hundred and fifty \i\ of plasma was taken in a microfiige tube and mixed with 50 
|j,l drug solution to be entrapped dissolved in PBS and adequate 0.35 M CaCb to 
obtain final 40 mM calcium concentration. 3.0 t^l aliquots of the mixture was 
transferred with the help of a micropipette as droplets at regular distance over a glass 
slide covered with Parafilm. The glass slides were kept in a Petri dish with wet 
blotting sheets on both the inner surfaces. Additional wet cotton was also placed in 
the lower plate to maintain moisture and prevent the plasma beads from drying. The 
Petri dishes were incubated at 37 °C for at least 40 minutes to facilitate clot formation. 
The beads were detached from the Parafilm surface, washed with normal saline and 
finally with PBS. 
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For some experiments beads were treated with various concentrations of 
glutaraldehyde. For this purpose, 30-35 beads were suspended in 1.0 mi PBS and 
glutaraldehyde solution was added to a final 0.08%, 0.01% or 0.05% (w/v) 
concentration of the crosslinking agent. These beads were incubated at 4 °C for 15 
minutes, washed thrice with normal saline and with 0.1 M glycine methylamine to 
remove unreacted glutaraldehyde and resuspended in PBS. 
2.2.4. In vitro Release of Entrapped Constituents from the Plasma 
Beads 
Sham plasma beads (30-35) or those containing entrapped constituents were incubated 
in PBS in a total volume of 1.0 ml. The samples were incubated at 25 °C and 10 ^1 
aliquot of the supernatant were withdrawn at various time intervals. Some beads were 
dissolved in 0.1 M NaOH for quantitaion of entrapped drug or protein. Also at the end 
of incubations the beads were collected, washed with PBS and dissolved in 0.1 N 
NaOH. Quantities of remaining protein and entrapped drugs were analysed in the 
solution. 
2.2.5. Spectrophotometric and Colorimetric Analysis 
2.2.5.1. Quantitaion of the drugs 
Amp B, tetracycline and daunorubicin were quantitated using spectrophotometic 
procedures by measuring their absorption at 405, 365 and 478 nm respectively (Mehta 
etal, 1987; Kumar e/a/., 2004; Simeonova er a/., 2009). 
2.2.5.2. Protein estimation 
Protein quantitation was performed according to the procedure described by 
Stoscheck (1990) using the BCA reagent. To the protein samples in a total volume of 
50 fil, 1.0 ml of BCA reagent (containing freshly prepared solutions A and B mixed in 
a ratio of 49:1) was added. The samples were incubated at 37 °C for 30 minutes and 
change in absorbance recorded at 562 nm. BSA was used as standard for the 
preparation of the calibration curve. 
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2.2.6. HPLC Analysis of Cefotaxime 
For cefotaxime quantitation, the protocol followed was that described by Eduardo San 
Martin (1999) with minor modifications made in our laboratory. A CI8 reversed 
phase column (250 mm x 4.6 mm) with the particle size 5 |am was used. The mobile 
phase comprised a mixture of 0.05M phosphate buffer pH 6.0 and acetonitrile (88:12, 
v/v). Flow rate was kept at 1.0 ml/minute and absorbance of the cefotaxime was 
measured at 254 nm. Separate curves were prepared for quantitation of cefotaxime in 
the plasma, liver and kidney samples. The slope and intercept of the calibration lines 
were determined by linear regression using least squares method. Fig.6 shows the 
calibration curve of cefotaxime prepared after extracting the drug fi"om plasma. 
Known quantities of cefotaxime were added to 200 i^l of plasma or tissue 
homogenates and the drug extracted used for preparing the calibration curves. 
The extractability of cefotaxime was determined by adding various amounts of the 
drug to the tissue homogenate and plasma and following the procedure of extraction 
described earlier (Eduardo San Martin, 1999) Between 95-97.3 percent of the added 
drug was extractable under the conditions used. 
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Fig.2.2.1. Calibration curve for quantitation of cefotaxime by RP HPLC. 
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2.2.6.1. Cefotaxime analysis in plasma 
To 200 |xl of plasma, 200 |al of acetonitrile was added and the tubes were Vortexed for 
30 sec. After centrifugation for 5 minutes at 1000 x g, the supernatant was added to 
2.0 ml of dichloromethane. The mixture was again thoroughly Vortex and centrifuged 
at 1000 X g for 10 minutes, and a 20 \x\ aliquot of supernatant was injected for drug 
analysis (Aguero et al, 1999). 
2.2.6.2. Cefotaxime analysis in tissues 
For tissue processing, weighed portions of liver and kidney were washed in PBS and 
traces of the buffer solution were removed by blotting with micro wipes. Specimens 
were then reweighed and 0.5 g tissues were homogenized using an Ultra Turrax T25 
homogenizer and enough cold saline added to obtain liquid volume 0.75 ml, which 
represents a tissue to liquid ratio of 1:1.5 (m/v). A volume of 1.2 ml acetonitrile was 
added to the homogenate in order to minimize the possible metabolic degradation of 
the antibiotic. The homogenates were centrifuged at 10,000 x g for 10 minutes and the 
resulting supematants extracted with dichloromethane as described earlier for plasma 
samples. Aliquots (usually 20 \i\) of the resultant supernatant were injected for drug 
analysis. HPLC analysis of each sample was performed at least in duplicate. The 
results were quantified by comparison of cefotaxime peak at 254 nm with standards of 
known concentration eluted at the same retention time. 
2.2.7. Vaccination of Mice against C. albicans Infection 
2.2.7.1. Preparation of the cytosolic antigen 
A strain of C. albicans was obtained from a patient admitted in the Jawaherlal Nehru. 
Medical College of the University, kindly made available by the Microbiology 
Department from their college repository. The culture was grown on Agar plates at 37 
°C for 24-48 h. Cells were collected in Falcon tubes and were washed thrice with 
saline in (1ml cells and 5 ml saline) to remove medium. Washed cells were 
mechanically disrupted with motor and pestle in a lysis buffer (50 mM tris HCl pH 
8.0, 100 mM NaCl and 1 mM EDTA). For each ml cells and 4.0 ml lysis buffer was 
used. This was followed by probe sonication (20 sec on and 5 sec off pulses for 2 
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minutes) in the presence of 0.1% (w/v) PMSF to restrict proteolysis. The homogenate 
was centrifuged at 8720 x g for 30 minutes at 4 °C and the supernatant was collected. 
Protein was partially purified by ammonium sulphate precipitation. The fraction 
obtained by 0-60% ammonium sulphate precipitation was discarded and the 
supernatant was collected. This was further subjected to 80% ammonium sulphate 
precipitation at 4 °C for 8 h and protein fraction was collected by centrifugation at 
8720 X g for 15 minutes at 4 °C. This precipitate was collected by dissolving in PBS 
and dialyzed extensively against the same. 
2.2.7.2. Preparation of liposome-based Cp antigen 
Liposomes were prepared by mixing egg PC (49 i^mol) and cholesterol (21 nmol) 
dissolved in 10 ml of chloroform and methanol (9:1). Egg PC/cholesterol (20 mg) was 
reduced to thin dry film under N2 atmosphere. The film was then hydrated, followed 
by sonication in a bath type sonicator (Hwashin Technology Co., Korea) for 1 h at 4 
°C. The liposomes thus formed were mixed at this stage with an equal volume of the 
Cp (Candida protein). The mixture was flash frozen and thawed (five cycles) and then 
passed through a Sepharose 4B column (1.3 x 51 cm). Fraction containing liposomes 
were collected and lyophilized. The free-flowing, dried powder thus obtained was 
rehydrated with desired volume of distilled water (Owais et al, 2000). 
The proteins entrapped in the liposomes were estimated as described elsewhere 
(Faisal et al, 2003). Briefly, the equal volume of sham liposomes and those 
containing Cp were lysed with 10% Triton X-100 solution added to a final 
concentration of 1% (w/v). BCA reagent was added to the lysed liposomes and the 
samples were incubated at 37 °C for 30 min. Absorbance was measured at 562 nm in a 
UV spectrophotometer and the protein concentration was calculated using a standard 
curve of BSA prepared in presence of triton X-lOO.The entrapment efficiency of Cp 
in the liposomes was about 20 percent. The zeta potential of liposomes containing Cp 
were -30 mV. 
2.2.7.3. Preparation of PLGA microsphere-based Cps antigen 
PLGA microspheres were prepared using water in-oil-in water (W/O/W) emulsion by 
the solvent evaporation technique (Jeffery et al, 1993). Briefly, Cp (15 mg dissolved 
in 0.5 ml PBS) was primarily emulsified with PLGA solution (190 mg PLGA 
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dissolved in 1.0 ml of DCM) using a bath type Sonicator. The primary emulsion was 
further mixed with 100 ml 10% (w/v) PVA and homogenized using the Silverson 
L4RT Homogenizer (Silverson Machines, East Longmeadow, MA). The resulting 
(0/W) emulsion was stirred at 25 °C for 18 h to allow solvent evaporation and 
microsphere formation. Microspheres formed thus were collected by centrifugation at 
10,000 X g for 10 minutes, washed with 20 PBS, lyophilized and stored at 4 °C till 
further use. Quantitation of the protein entrapped in the PLGA microsphere was 
carried out by the BCA procedure. Briefly, known volumes of sham PLGA 
microspheres and those containing Cp were dissolved in 0.1 N NaOH solution. BCA 
reagent was added to the lysed PLGA microspheres (released protein) and the sham 
samples and then incubated at 37 °C for 30 min. Absorbance was measured at 562 nm 
in a UV spectrophotometer and the protein concentration was calculated using a 
calibration curve prepared using BSA. The entrapment efficiency of Cp in PLGA 
microsphere was 30-35 percent. 
Fig. 2.2.2 shows the scarming electron microscopic image of the PLGA microsheres 
prepared as described above. The preparation contained nearly spherical particle. The 
particle size and Zeta potential of the PLGA microsphere was measured by the 
instrument Zetasizer Nano ZS using DTS software (Malvern Instrument Limited, 
UK). The Zeta average diameter and zeta-potential of the Cp loaded microspheres as 
in the (Fig.2.2.3) is found to be in the range of 600-900 nm and -30±0.45 mV. The 
SEM of the microspheres was performed, courtesy Electrom Microscope Facility, 
Jawaherlal Nehru University, New Delhi. 
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Fig.2.2.2. SEM image of PLGA microspheres 
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2.2.7.4. Immunization of mice 
Inbred female Balb/c mice were used for the study. Each group consisted of 12 
animals. Groups of mice were injected through subcutaneous route, a total two doses 
(on days 0 and 14) of various preparations of Cp. These included Cp entrapped in 
PLGA microspheres (PLGA-Cp) PLGA-Cp further entrapped in fibrin crosslinked 
plasma beads (Fib-PLGA-Cp), Fibrin crosslinked plasma bead entrapped Cp (Fib-
Cp), Cp emulsified with Incomplete Freund's adjuvant (IFA-Cp), Cp alone (Cp) or 
PBS only. Similarly for the parallel set of experiments with liposomes, the 
formulations used for immunization were; liposome-encapsulated Cp (Lip-Cp), Lip-
Cp further entrapped in the fibrin crosslinked plasma beads (Fib-Lip-Cp), and 
controls- Fib-Cp, IFA-Cp, Cp alone and saline All the animals received a priming 
dose of the preparation containing 100 i^ g Cp protein per animal and boosted with 60 
|ig of Cp per animal on days 14. 
2.2.8. Enzyme Linked Immunosorbant Assays 
2.2.8.1. Measurement of Cp-specific IgG 
Formation of antibodies against the ammonium sulphate fractionated Cp was 
evaluated using indirect ELISA (Agrewala et al, 1998). Microtiter plate wells were 
coated with 5 |ig Cp antigen. Sera from animals of the each experimental groups 
were diluted 100 fold and added in the first well and sera serially diluted up to 12,800 
fold were added in subsequent wells. The plates were incubated at 37 °C for 2 h 
washed/ aspirated three times with the PBST, and 100 ^1 of 5000 fold diluted HRP 
conjugated rabbit anti mouse IgG (Genei, India), that served as the secondary 
antibody was added. The plates were incubated for 1 h at 37 °C washed/aspirated six 
times with the PBST and 100 i^ l substrate (6.0 mg ortho-phenyl diamine in 12.0 ml 
citrate buffer and 5.0 \i\ H2O2) was added. The plates were incubated 15 minutes at 37 
°C and reaction terminated by adding 50 ^1 1.0 M H2SO4. Absorbance of the 
developed color was recorded at 492 nm. 
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2.2.8.2. Cp-specific IgG isotypes 
For assessment of IgG subclasses of the antibodies generated against Cp, sera were 
collected day 10 of immunization and day 5 of booster. Costar (Dynatech, Chantilly, 
VA) microtiter plates were coated overnight with Cp (5 iig/well) in bicarbonate buffer 
pH 9.5 at 4 °C. The plates were blocked with 200 ^1 of 1% (w/v) BSA in PBS and 
kept at 4 °C for over night or at least 2 h at 37 °C. The blocking solution was 
aspirated, and the wells washed at least six times with PEST. Individual mouse sera 
were diluted 100 fold in 1% BSA in PBST and 100 \il of this diluted preparation was 
added to the wells of the microtitre plates. The plates were incubated at 37 °C for 2 h 
and washed six times with PBST. One hundred |al aliquots of the isotype-specific goat 
anti-mouse monoclonal antibodies (anti mouse IgGl or IgG2a) in 1% (w/v) BSA in 
PBST diluted 5,000 fold were added to the wells and the plates incubated at 37 °C for 
1 h. The wells were again washed six times with PBST and 100 ^1 rabbit anti-mouse 
IgG HRP conjugate, that serve as a secondry antibody, was added to each well. The 
plates were further incubated at 37 °C for 15 minutes, reaction terminated by adding 
50 |il 1.0 M H2SO4 and absorbance recorded at 492 nm in an ELISA reader. 
2.2.8.3. Splenocyte proliferation assay 
The splenocytes proliferation assay was performed using the published protocol 
(Owais and Gupta, 2000). On day 5 after the administration of the booster, two mice 
from each group were sacrificed for the splenocytes proliferation assay. Spleens were 
aseptically removed from anaesthetized mice and washed with PBS. Splenocytes were 
isolated by maceration of spleens following the protocol described by Reeves and 
Reeves (2001). Erythrocyte in spleen cell preparation were lysed by mixing two parts 
of spleen preparation with one part of Gey's solution and the splenocytes collected by 
centrifugation at 204 x g for 10 minutes. The cells were washed with RPMI 1640 
medium containing 10% fetal calf serum. Viable cells were counted by 0.1% Trypan 
Blue dye exclusion method. In order to perform the proliferation assay, the cells were 
diluted and 4xl0Vl00 |al per well in 96 well flat bottom microtitre plates. For 
stimulation index 20 |ig antigen was added in first well and it was further serially 
diluted to obtain a concentration of 2.5 |xg in last well. Concanavalin A (ConA) and 
plain RPMI were used as positive and unstimulated controls, respectively. Cells were 
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incubated for 72 h at 37 °C with 5% CO2 in a CO2 incubator (Binder, Germany). After 
72 h, 20 |il MTT solution (5 mg/ml) was added to each well. The plates were 
incubated in the CO2 incubator for 2 h. At the end of incubation, medium was 
aspirated, 100 ^l of DMSO or lysis buffer was added to the each well and the contents 
mixed to dissolve the any formed crystals. The plates were incubated for 5 h at 37 °C 
and read at 550 nm with reference at 630 nm. 
The stimulation index (S.I.) was calculated using following formula: 
S.I. = [Absorbance of the experimental group] - [Absorbance of the control] / 
[Absorbance of the control group] 
2.2.8.4. Gamma-interferon (IFN-y) levels 
IFN-y was estimated by antigen capture ELISA using the B.D. Biosciences (India) 
assay kit. The culture supematants were set up as described for cell proliferation study 
and then stimulated with 20, 10, 5, and 2.5 |jg of Cp in RPMI containing 10% fetal 
calf serum (Sigma, USA). After 48 h of incubation at 37 °C in humidified atmosphere 
(5% CO2), the plate was centriftiged at 400 x g at 4 °C and the supernatant collected. 
Interferon-y content was determined in triplicate wells by ELISA using microtitre 
plates (Nunc, Denmark) coated with anti-mouse IFN-y antibody. After thorough 
washing, the wells were blocked for 2 h at room temperature with 200 |al of blocking 
solution (1% BSA w/v in PBS). Cell culture supernatant were plated at 1:10 dilution 
in the blocking buffer, the plates incubated for 2 h at room temperature and washed 
five times with PBS containing 0.05% Tween-20. The bio-tynilated anti-mouse IFN-y 
and avidin-HRP conjugate were used according to the manufacturer's instruction. 
Activity of the bound HRP was determined by adding the TMB substrate. The plates 
were read in a ELISA reader at 450 nm 30 minutes after the addition of the stopping 
solution (1.0 M H2SO4). All assays were performed in triplicate and the IFN-y 
concentration in the culture supernatant was expressed as picogram per milliliter 
(pg/ml) as computed using the calibration curve prepared using pure recombinant 
IFN-y. 
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2.2.8.5. IiiterIeukin-4 (IL-4) levels 
Interleukin-4 (IL-4) was quantitated by the antigen capture ELISA using BD 
Biosciences assay kit. The culture supernatant were set up as described for cell 
proliferation study and then stimulated with different amount of the antigens. After 48 
h incubation at 37 °C in humidified atmosphere (5% CO2), the plates were centrifuged 
at 400 X g at 4 °C and the supernatant collected. Interleukin content was determined in 
triplicate wells by ELISA using microtitre plates (Nunc, Denmark), coated with anti-
mouse IL-4 antibody. After thorough washing, the wells were blocked for 2 h at room 
temperature with 200 |J1 of BSA solution (1% w/v BSA in PBS). Cell culture 
supernatant were plated at 1:10 dilution in the blocking buffer and incubated for 2 h at 
room temperature. The plates were washed five times with PBS containing 0.05% 
Tween-20. Bio-tinylated anti mouse IL-4 and avidin-HRP conjugate were used 
according to the manufacturer's instruction and the assay carried out by adding TMB 
substrate. Plates were read at 450 nm within 30 minutes after the addition of the 
stopping solution (1.0 M H2SO4). All assays were performed in triplicate and the lL-4 
concentration in the culture supernatant was expressed as picogram per milliliter 
(pg/ml) as computed from the calibration curve prepared using standard rIL-4. 
2.2.9. Measurement of DTH response 
In another set of experiment animals (each group had 3 animals) were immunized 
with various preparations in the inguinal region and ten days after injection of 
antigen-containing or control reagents, the mice footpad were tested to determine their 
DTH reactions to Cp (Buchanan and Murphy, 1993). DTH reactions were elicited by 
injection of 50 (xg of Cp in the right footpad of each mouse and saline into the left 
footpad. The thickness of each footpad was measured just before injection and after 
36 h of post injection of Cp or saline using a gauge calipers (Mitutoyo dial calipers). 
DTH reactions were evaluated by the increase in footpad thickness as determined by 
the following formulae (right footpad at given hours - right footpad at 0 hrs) - (left 
footpad at given hrs - left footpad at 0 hrs). 
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2.2.10. Determination of NO concentration 
NO, quantified by the accumulation of nitrite in the culture medium, was measured as 
described elsewhere (Ding et al, 1988). On day 15 post immunization, two mice from 
each group were sacrificed for the isolation of peritoneal macrophages. Briefly, 
peritoneal macrophages (IxlO^cells/animal) from the mice of various experimental as 
well as control groups were cultured in culture plates and pulsed with the Cp (final 
cone. 10 ng/well). After 24 h of incubation, 100|J1 of culture supernatant was 
collected from each well and subsequently mixed with an equal volume of Griess 
reagent (1% sulphanilamide and 0.1% iV-(l-napthyl) ethylenediamine dihydrochloride 
in 2.5% H3PO4] and further incubated for 10 min at 25 °C. Absorbance of thus 
formed colored complex was determined at 550 nm in an ELISA reader. 
2.2.11. Staining for T cell and co-stimulatory surface markers 
Various surface markers of antigen presenting cells (APS) were also studied. The 
splenocytes were harvested as described earlier for cell proliferation assay and 1x10^ 
cells were taken into microfuge tubes containing 1.0 ml FACS buffer (PBS with 1% 
BSA and 0.1% sodium azide) and washed twice with the same buffer and centrifuged 
at 204 x g for 10 min. To the cells was added the Fc block (2.4 G2), followed by 125 
ng of FITC/PE tagged monoclonal antibodies (CD4, CD8, CD80, CD86 or anti-
isotype control). The tubes were incubated at 4 °C for 30 minutes, the splenocytes 
washed twice with the FACS buffer to remove unbound antibodies and fixed with 1% 
(v/v) paraformaldehyde. The cytometry data was obtained using a fluorescence 
activated cell sorter and data analyzed using the express plus softwere (GUAVA, 
USA). 
2.2.12. Assessment of protection against challenge with C. albicans 
A total of two doses of Cp 100 fig/animal on day 0 and 60 )ig/animal on day 14 were 
injected in the animals of various groups PBS, sham fibrin, Cp, IFA-Cp, Fib-Cp, 
PLGA-Cp and Fib-PLGA-Cp subcutaneously. On the day 5 post booster two animals 
from each group were sacrificed for FACS and cytokines analysis. Rest ten animals 
from each group were used for protection studies. On day 7 post booster, mice were 
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challenged with C. albicans cells (Ix 10^  cells per animal) by intravenous route to 
induce the experimental disseminated candidiasis. Survivals of animals were 
monitored for a period of one month in order to assess the protective effect of various 
formulation of vaccine. 
2.2.13. Determination of fungal load in blood, kidney and spleen 
Fungal load in blood was used as a parameter to establish the extent of C. albicans 
infection in the immunized mice. Blood was collected aseptically from various groups 
of immunized and control mice by retro-orbital puncture in anticoagulant solutions on 
day 5 and day 30 day post infection. The animals were sacrificed on day 5 and 30 post 
infection, their kidneys and spleen were taken out aseptically and washed extensively 
with hypotonic buffer, homogenized and serially diluted with normal saline. Blood 
(50 nl) or appropriately diluted kidney and liver homogenates from the mice of 
various experimental groups were plated in triplicate on YPD agar plates. After 
incubation for 48-72 h at 37 °C, the colonies were counted and fungal load calculated 
by multiplying the number of CFU with respective dilution factor. 
2.2.14. SDS-PAGE of the Proteins 
SDS-PAGE analysis was carried out as described by Laemmli (1970) in a vertical 
mini-gel electrophoresis apparatus (ATTO, Japan) using 10% (w/v) resolving gel and 
5% (w/v) acrylamide stacking gel. Electrophoresis was carried initially at 9 mA to 
facilitate the stacking of the sample and current subsequently raised to 18 mA. 
Electrophoresis was performed until the tracking dye reached the bottom of the gel. 
The gels were then taken out from the plates and stained with 0.1% (w/v) Coomassie 
Brilliant Blue R-250 (prepared in methanol, glacial acetic acid and water in 45:10:45 
ratio). The gels were destained with a solution containing ten parts each of methanol 
and glacial acetic acid and eighty parts of water. 
2.2.15. Statistical Analysis 
All the data were analyzed by one-way analysis of variance (ANOVA) following 
Dunnett t- test method. Values of P < 0.05 were considered statistically significant. 
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3.0. RESULTS 
3.1. PREPARATION OF BEADED PLASMA CLOTS STABILIZED BY 
CROSSLINKED FIBRIN AND EVALUATION OF THEIR DRUG RELEASE 
BEHAVIOR. 
Blood clotting is a spontaneous process accompanying injury and the clotting cascade 
has been studied and understood extensively. The remarkable ability of thrombin to 
convert fibrinogen to fibrin clot has been exploited to develop surgical sealants not 
only to stop bleeding but also to provide scaffold for tissue regeneration and to deliver 
some pharmaceuticals mainly for sustained release and infection control. A number of 
preparations that used pure fibrinogen and thrombin along with activated factor III 
(transglutaminase) have been used and continue to be used as sealEints in a variety of 
forms. In addition, attractive features like biocompatibility, biodegradability, ease of 
preparation, potential for modification of fibrin matrices have attracted numerous 
investigations on their potential as effective drug delivery systems. 
The risks of immunological complications arising out of the use of commercial fibrin, 
thrombin and factor III preparations, especially due to the use of bovine thrombin, are 
well known (Nichols, 1994), While autologous fibrinogen preparations and use of 
recombinant human thrombin in place of the bovine enzyme seem to address the risks 
to a large extent (Jackson, 2001), such preparations continue to be expensive. We 
attempted preparing clots fi"om plasma, obtained from blood collected in presence of 
the chelating agent EDTA, by adding excess CaCl2. The clots could be prepared in the 
form of small beads facilitate study of release of the entrapped substances. 
3.1.1. Determination of clotting time of plasma 
Fresh plasma isolated fi-om the rabbit blood, collected in presence of EDTA was 
induced to clot as described in methods by addition CaCli and clot formation 
monitored by measuring the resulting turbidity at 595 nm (Bale and Mosher, 1986). 
Addition of up to 24 mM CaCl2 to the plasma resulted in a gradual time dependent 
increase in the turbidity, reaching a plateau in about 20-30 minutes (Fig.3.1.1.) The 
increase in turbidity was however steeper and attained higher value in 18 minutes 
when 32-40 mM CaCli was added. Maximum turbidity reached at these 
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concentrations of CaCh was almost double of that observed at lower salt 
concentrations, suggesting optimum clot formation. Increase calcium concentrations 
above 40 mM however resulted in decrease, both in the rate and magnitude of the 
developed turbidity. The clot formed at 40 mM CaCb appeared stable and the 
concentration was used for the preparation of plasma beads during the remaining 
study. Comparable concentrations of CaCh have been used for the formation of fibrin 
sealants from purified fibrinogen and thrombin (Radosevich et al, 1997). 
3.1.2. Preparation of the beaded plasma clot 
In order to prepare the plasma beads 125 |il of the plasma was mixed with 15 \x\ oi 
0.35 M CaCb in distilled water. Aliquots (0.5-10 nl) of the plasma with the added 
CaCb were rapidly transferred in the form of tiny droplets separated from each other 
with the help of a micropipette to a slide covered with Parafilm. The slides were 
incubated in Petri dishes lined with moist filter paper at 37 °C for at least 40 min. Clot 
formation transformed the plasma droplets to small nearly spherical beads, which 
were subsequently detached from the Parafilm surface, transferred to Eppendorf tubes 
and washed thoroughly with phosphate buffered saline. In order to determine the 
quantity of the pharmaceuticals entrapped, the washed beads were dissolved in 0.1 M 
NaOH and the released drugs were rapidly quantitated using specific procedures 
described below. Presence of NaOH did no affect the absorption behavior of the 
drugs under the conditions used in the study. 
The plasma beads, especially those formed with small volumes (0.5-3.0 \i\) of the 
calcium-enriched plasma were nearly spherical but those prepared with larger 
volumes of plasma resembled somewhat flattened discs (Fig. 3.1.2). The average 
diameter of the beads ranged between 1.08 to 2.75 mm respectively, for beads 
prepared respectively with 0.5 |il and 10 |il plasma (Table 3.1.1.). Fig. 3.1.3. shows 
the effect of size of the plasma bead on release of entrapped tetracycline on incubation 
in phosphate buffered saline. There was observed an inverse relationship between the 
size of the bead and leakage of the antibiotic in the medium. Beads prepared using 3.0 
Hl plasma (mean diameter 1.92 mm) released over 90 percent tetracycline in 60 hours 
while those with a mean diameter of 2.75 mm (10 |il plasma) released only about 70 
percent of the entrapped antibiotic. This is in agreement with the observations made 
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earlier that entrapped drugs are released more slowly from larger beads (Ho et al, 
1995). Unless mentioned otherwise beads prepared from 30 nl plasma were used in 
the studies. 
3.1.3. Polypeptide composition of the plasma beads 
The polypeptide composition as revealed by SDS-PAGE of the plasma beads was 
comparable with that of rabbit plasma (Fig.3.1.4), with the band corresponding to 
albumin constituting the major component. The beads were stable and retained nearly 
their original shape after incubation up to five days in phosphate buffered saline pH 
7.4. The incubation however resulted in loss of 20-30 percent of polypeptides and 
additional appearance of those of large and small molecular weight. Crosslinking of 
the beads with glutaraldehyde resulted in concentration dependent formation of 
additional high molecular weight poly peptides (Fig. 3.1.5). 
3.1.4. Release of proteins from the plasma beads 
Fig. 3.1.6 shows the time dependent release of proteins from the plasma beads 
incubated in PBS at 25 °C for up to 130 hours. The release of proteins from the 
plasma beads was slow and only about 20 percent of total bead proteins were 
released. Co-entrapment of aprotinin (3000 KlU/ml plasma) in the beads did not 
remarkably affect the release of proteins from the plasma beads. The differences in 
protein released from the beads containing aprotinin and those without were 
comparable and moderate but small and insignificant differences were however 
apparent after 50 hours of incubation. The proteins released from the beads contained 
nearly all the plasma proteins and there was apparent no difference preferential 
release of proteins according to their molecular dimensions (Fig.3.1.7). 
3.1.5. Release of entrapped drugs from the plasma beads 
Figs. 3.1.8 shows the profiles of release of the antibiotic tetracycline and the anti-
cancer drug daunorubicin from the plasma beads prepared as described and also 
subjected to crosslinking with glutaraldehyde. Release of tetracycline was markedly 
low as compared to that of daunorubicin with only 50 percent of the drug being 
released in 20 hours. Most of the antibiotic was however released in about 100 hours. 
Crosslinking with glutaraldehyde resulted in marked decrease in the release of the 
antibiotic from the beads. There was evident a clear inverse relationship between the 
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leakage of the antibiotic from the beads and concentration of glutaraldehyde used for 
crossUnking. Plasma beads crosslinked with 0.05 percent glutaraldehyde retained 
nearly 50 percent of the entrapped antibiotic after incubation for 100 hours. 
Daunorubicin was released far more rapidly from the beads with more than 90 percent 
of the drug leaking out of the beads in about 24 hours and nearly all the drug was 
released in 48 hours. Release of the daunorubicin was also decreased remarkably 
when the beads were cross-linked with glutaraldehyde. Beads crosslinked with 0.008, 
0.01 and 0.05 percent glutaraldehyde leaked only 63, 57 and 47 percent of the 
entrapped daunorubicin respectively, after incubation for 52 hours. The 
glutaraldehyde treated beads retained significant quantities of tetracycline even after 
incubation in PBS for 100 hours. 
Amphotericin B release from the plasma beads was most slow presumably because of 
its ability to bind strongly to the plasma proteins (Brajtburg et al, 1984; Bekersky et 
al, 2002). As evident from the Fig. 3.1.9, less than 40 percent of the drug was 
released on incubation of the antifiingal containing beads for over eight days. As 
observed in case of daunorubicin and tetracycline, the release of amphotericin B could 
be ftirther lowered remarkably by crossUnking the beads with glutaraldehyde. 
3.1.6. In vivo release of cefatoxime 
In a preliminary in vivo study, a comparison of administration of free cefotaxime and 
that entrapped in plasma beads and the plasma concentration of the drug was carried 
out in Balb/c mice. Cefotaxime is a semi synthetic third generation of cephalosporin 
antibiotic used in the treatment of serious infections caused by a variety of susceptible 
both gram-positive and gram-negative organisms (Karakusis et al, 2005). 
As evident from the Figure 3.1.10, the plasma concentration of cefotaxime were 
maximum four hours after the administration of the free drug and the level declined 
rapidly and was undetectable after 100 hours. Plasma levels of the drug in animals 
receiving the fibrin bead entrapped preparation reached peak after 24 hours and 
declined gradually reaching a concentration of 0.4 ng/ml after 136 hours. The 
observations indicate that release of the antibiotic from the fibrin beads is also gradual 
in vivo. Cefotaxime analysis in the kidneys suggested the presence of lower 
concentration of the drug in the groups of animals administered the bead entrapped 
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formulations (Fig. 3.1.11.). This was surprising since plasma concentration of the 
antibiotic was markedly higher in groups receiving the plasma bead entrapped 
formulation over the period of investigation. Accumulation of cefatoxime in liver was 
however comparable in the groups receiving the drug either in free form or after 
entrapment in the plasma beads (3.1.12.). 
0.5 -I 
-^ C.4 • 
ON 
o 
5 
0.3 -
C5 0.2 
0.1 
8 12 16 20 
Tiiue (iiiiiis.) 
24 28 
Fig.3.1.1. Effect of CaCh on clot formation in plasma. Aliquots of rabbit plasma 
containing various concentrations of CaCb in a total volume of 140 fal were incubated 
in a 96 well plate at 37 ''C and turbidity determined at 595 nm in an ELISA plate 
reader. The samples contained (A) 4.0 mM, (—) 8.0 mM, (-) 16 mM, (•) 24 mM, (o) 
32 mM, (X) 40 mM, (A) 48 mM, (D) 58 mM, or ( • ) 64 mM CaCb Each value 
represents the mean of three closely agreeing (variation < 10%) values. 
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Fig.3.1.2. Photograph of beads prepared using various volumes of plasma. Beads 
prepared using 3.0 jil (A), 1.0 [i\ (B) and O.Sjil (C) of calcium enriched plasma are 
shown (3X Optical Zoom) (Scale are shown in mm). 
Fig.3.1J. Effect of bead dimensions on the release of tetracycline from the 
plasma beads. Plasma beads of various dimensions were prepared by varying the 
volume of calcium enriched plasma transferred to the Parafilm covered slides. Beads 
with diameter 1.92 ±0.141 {•); 2.15±.0.I36 (A); 2.35±0.111 (0); and 2.75±.0.250 (A) 
mm were used. Values represent mean ± of five determinations 
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Fig.3.1.4. SDS PAGE of plasma beads. Plasma beads prepared as described in the 
text were dissolved in sample buffer immediately after preparation or after incubation 
in PBS as described under Methods. Lane 1, protein molecular weight markers; Lane 
2, rabbit plasma; Lane 3, fresh plasma beads: Lane 4, plasma beads incubated in PBS 
for five days. (Proteins loaded in each lane is 35 ng) 
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Fig.3.1.5. SDS-PAGE of glutaraldehyde-treated plasma beads. Beads prepared 
using rabbit plasma was treated with various concentrations of glutaraldehyde as 
described under Methods. Lanel, protein molecular weight standards; Lane 2, rabbit 
plasma; Lane 3-5, plasma beads treated with 0.008, 0.01 and 0.05 percent 
glutaraldehyde respectively. 
(Proteins loaded in each lane is 35 |ag). 
64 
140 
Fig. 3.1.6. Release of proteins from the plasma beads. Plasma beads (3.0 \x\ /1.93 
mm mean diameter) were incubated in phosphate buffer saline at 25 °C and release 
profiles of protein were estimated by BCA reagent. Sham plasma beads (T); Plasma 
beads containing aprotinin (•). Each value is the mean of three independent 
experiments ±SD. 
65 
1 2 3 4 5 6 7 8 
205 
97 
68 
45 
29 
20 
i 
Fig. 3.1.7. SDS-PAGE of proteins released from the plasma beads. Beads prepared 
using rabbit plasma were described in the material method section. Lanel, protein 
molecular weight markers; Lane 2, 3, 4, 5, 6, 7 shows the protein released at 4, 20, 56, 
80 104 and 128 hrs respectively. (Lane 1, 2, 3, 4 and 5-7 were loaded 10, 20, 25 and 
30 ng proteins respectively). Lane 8 contains plasma proteins (40 |ig). 
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Fig.3.1.8. Release of daunorubicin (A) and tetracycline (B) from the plasma 
beads. Plasma beads containing entrapped daunorubicin (50 |xg) and tetracycline (50 
l^ g) were incubated in PBS at 25 °C and release profiles of the drug was studied 
spectrophotometrically as described under Methods. Control plasma beads (n); 
Plasma beads treated with 0.008% glutaraldehyde (•); 0.01% glutaraldehyde ( • ) ; or 
0.05% glutaraldehyde (A). Each value represents mean ±SD of five determinations. 
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Fig.3.1.9. Release of amphotericin B from the plasma beads. Plasma beads 
containing entrapped amphotericin B (100 |j.g) were incubated in phosphate buffer 
saline at 25 °C and release kinetics of drug was determined spectrophotometrically as 
described under Methods. Control plasma beads (D); Plasma beads treated with 
0.008% glutaraldehyde (•), 0.01% glutaraldehyde ( • ) , or 0.05% glutaraldehyde (A). 
Each value represents mean ±SD of five determinations. 
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Fig.3.1.10. Cefotaxime concentrations in the plasma of mice subcutaneously 
administered the antibiotic. Animals received 50 mg/kg body weight of cefotaxime 
dissolved in normal saline (A) or entrapped in the plasma beads (A). The animals 
were bled at various intervals and plasma concentration of the antibiotic determined 
by HPLC as described. Each value represents the mean ±SD of five determinations. 
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Fig.3.1.11. Cefotaxime concentrations in the kidneys of mice subcutaneously 
administered the antibiotic. Animals received 50 mg/kg body weight of cefotaxime 
dissolved in normal saline in free form (n) or entrapped in the plasma beads (•). The 
animals were sacrificed at various intervals and kidney tissue concentration of the 
antibiotic determined by HPLC procedure as described. Each value represents the 
mean ±SD of five determinations. 
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Fig.3.1.12. Cefotaxime concentrations in the Liver of mice subcutaneously 
administered the antibiotic. Animals received 50 mg/kg body weight of cefotaxime 
dissolved in normal saline in free form (n) or entrapped in the plasma beads (•). The 
animals were sacrificed at various intervals and liver tissue concentration of the 
antibiotic determined by HPLC as described. Each value represents the mean ±SD of 
five determinations. 
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Table 3.1.1. Diameters of the beads prepared using various volumes of calcium 
enriched plasma 
Volume of plasma(^l) Diameter (mm* (Mean ± SD) 
10.0 ^l 2.75±0.250 
7.5^1 2.35±0.111 
5.0 i^l 2.15±0.136 
3.0^1 1.92±0.141 
1.0^1 1.30±0.111 
0.5^1 1.08±0.129 
*Plasma beads prepared using various volumes of calcium em-iched plasma were 
prepared and photographed along with a scale (mm). The photograph was magnified 
and diameters were measured with the scale. Each value represents the mean of five 
determinations. 
72 
3.2. STUDIES ON THE EFFICACY PC/CHOL LIPOSOMES AND FIBRIN 
CROSSLINKED PLASMA BEADS AS C. ALBICANS ANTIGEN DELIVERY 
SYSTEMS 
The objective of the studies described in this chapter was to compare the usefulness of 
Hposome encapsulation and entrapment in the fibrin crosslinked plasma beads in 
enhancing the immunogenicity of the partially purified antigen (Cp) from C. albicans 
as well as the immunoprotection potential against challenge by the fungus. 
Appropriate controls comprising Cp that was injected alone or with the Freund's 
Incomplete Adjuvant (IFA) were also included in the study. The formulations of Cp 
used included in the study were an emulsion of Cp with IFA (IFA-Cp), Cp entrapped 
in Fibrin-crosslinked plasma beads (Fib-Cp), Liposome encapsulated Cp (Lip-Cp) and 
Liposome encapsulated and fibrin cross-linked plasma bead entrapped Cp (Fib-Lip-
Cp). Care was taken to ensure that all formulation used for immunization contained 
same quantities of the fiingal antigen. 
The objective of this set of experiments was to investigate the effect of immunization 
of animals with various Cp formulations on their humoral, cell mediated immunity as 
well in offering protection against challenge with live C. albicans cells. 
3.2.1. Preparation of C.albicans antigen 
C. albicans cytosolic cell lysate contains a highly heterogeneous mixture of proteins. 
A partially purified fraction of the Candida antigen was prepared by subjecting the 
lysate to sequential ammonium sulphate fractionation. As shown in Fig. 3.2.1, 
fractions precipitated at lower ammonium sulphate saturation contained relatively 
large molecular weight proteins, while the 60-80 percent fraction contained those 
mainly ranging between 25-95 kDa. The 60-80 percent ammonium sulphate fraction 
was used as the antigen (Cp) in this study. 
3.2.2. Humoral response in mice administered various Cp formulation 
The levels of Cp-specific total IgG in the sera of all immunized as well as control 
animals were determined by ELISA as described earlier. As shown in Fig. 3.2.2a, 
Maximum increase in total IgG levels were observed in the animals immunized with 
Fib-Lip-Cp followed by Lip-Cp and Fib-Cp on day 10 post immunization. Compared 
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to the groups receiving PBS or the sham beads, those injected with Cp revealed 
significantly higher level of circulating IgG. The IgG levels rose markedly when a 
combination of the adjuvant and Cp was administered, although the levels in the later 
were also clearly lower than those in the other three groups in the order Fib-lip-Cp> 
Lip-Cp>Fib-Cp> Cp>. Day 5 post booster the levels of total IgG in all the Cp 
receiving groups were proportionately increased with Fib-Lip-Cp clearly showing 
highest level. 
The antibody isotype analysis data show a marked increase IgG2a level in Lip-Cp, 
Fib-Cp and Fib-Lip-Cp groups as compared to others. The IgG2a levels of Fib-Lip-Cp 
were also significantly higher as compared to those of Lip-Cp and Fib-Cp {P < 0.01). 
Beside IgG2a, the predominant isotype generated by Fib-Lip-Cp was IgGl. Lip-Cp 
and Fib-Cp formulations that up-regulated IgG2a level in the sera of immunized 
animals (Cp vs Lip-Cp p<0.001; Cp vs Fib-Cp p<0.05), also elevated IgGl level that 
however was significantly lower than that of the Fib-Lip-Cp group (P < 0.001). 
3.2.3. DTH response in mice receiving the Cp formulation 
It is now well recognized that cell mediated immune response (CMI) plays an 
important role in the control of infection by intracellular pathogens. For example 
DTH, which is an in vivo manifestation of CMI, has been shown to parallel the 
development of protective immunity in mice (Mallick et al, 2007). As evident from 
Fig.3.2.3, the animals immunized with Fib-Lip-Cp induced the strongest DTH 
response (footpad thickness 63 mm) when compared with Lip-Cp and Fib-Cp 
administered groups (foot pad thickness 49 and 45 mm respectively).While only 
moderate DTH response was evident in animals receiving IFA-Cp, the response was 
minimal in the remaining groups. 
3.2.4. Nitric oxide production in mice receiving the Cp formulations 
A number of cytotoxic substances are produced by activated macrophages to counter 
the attack by pathogens. Nitric oxide (NO) is one of such products, which is a useful 
index of the number of activated macrophages present in the various preparations. 
Peritoneal macrophages isolated from the immunized mice belonging to various 
groups were cultured in complete RPMI and incubated with the Cp either for 5 or 6 
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day 15 (final concentration 10 |ag/well). After incubation, 100 |il of the supernatant 
was collected fi-om each well and NO production estimated as described under 
methods. Generation of highest NO in response to immvmization with Fib-Lip-Cp 
(Fig. 3.2.4) suggests the up-regulation of inducible NO synthase (iNOS, N0S2) by 
Thl associated cytokines (Sharma et al, 2005). Supematants from cultures derived 
from almost all groups of immunized animals showed elevation in NO levels, but 
those from Fib-Lip-Cp showed highest levels. Increase in NO levels in groups 
receiving PBS and sham beads were not significant. 
3.2.5. Induction of IFN-y in splenocytes of the immunized mice 
In order to fiarther evaluate the CMI response generated by the antigen formulations, 
the type 1 cytokine, IFN-y levels were estimated in culture supematants of 
splenocytes stimulated with the antigen (Fidel et al., 1993). IFN-y from the 
splenocytes collected day 5 post booster from groups of animals receiving various Cp 
formulations were cultured with respective formulation and IFN-y levels in the 
cultures supematants were determined. Fib-Lip-Cp formulation was again effective in 
inducing highest level of IFN-y (325 pg/ml) in the stimulated cells. Among other 
forms of Cp preparations, Lip-Cp and Fib-Cp showed significant increase in level of 
IFN-y. While, it was 101 pg/ml in IFA-Cp group {P < 0.05). Animals immunized with 
free form of Cp failed to elicit significant level of IFN (Fig. 3.2.5). 
3.2.6. Expression of the type II cytokine IL-4 in the immunized mice 
Animals immunized with various formulations of Cp also showed remarkable 
differences in the level of IL-4 secreted in the culture supematants. In the splenocytes 
of animals immunized with Fib-Lip-Cp, the observed levels of IL-4 (123 pg/ml) 
were lower as compared to that from those immunized with the Lip-Cp (IL-4, 133 
pg/ml) and that of Fib-Cp (IL-4, 135 pg/ml). IL-4 formation in case of the animals 
receiving PBS was significant and comparable to that of those receiving Fib-Lip-Cp 
(Fig.3.2.6.). 
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3.2.7. Antigen induced proliferation of splenocytes derived from the immunized 
mice 
The potential of various forms of Cp to induce the proHferation of antigen-specific T 
lymphocytes was also studied. Splenocytes obtained from mice immunized with Fib-
Lip-Cp, Lip-Cp or Fib-Cp revealed high proliferation rates when compared with those 
from animals immunized with IFA-Cp or fi-ee form of Cp (Fig. 3.2.7.). Splenocyte 
responsiveness to antigen was found to be maximum in the group immunized with 
Fib-Lip-Cp followed by those of Lip-Cp and Fib-Cp groups. Control groups, 
containing cells obtained from animals immunized either with free Cp or PBS, failed 
to induce significant T cell proliferation. 
3.2.8. Expression of the co-stimulatory molecules CD80 and CD86 on the surface 
ofAPCs 
Flow cytometric analysis was conducted to evaluate the expression of CD80 and 
CD86 on the surface of APCs isolated from groups of animals immunized with Fib-
Lip-Cp or Fib-Cp as described under methods. The data shown in Fig 3.2.8a and 
3.2.8b reveal that APCs isolated fi-om animals immunized with Fib-Lip-Cp showed 
significantly higher level of expression of both CD80 (9.4%) and CD86 (14%) on 
their surface (Fig.7a and 7b). In contrast, APCs isolated from animals immunized 
with Fib-Cp expressed clearly lower levels both of CD80 and CD86 respectively. 
3.2.9. Expression of CD4* and CD8* on the surface of T lymphocyte 
Flow cytometric analysis was also conducted to determine the expression of CD4'^  
and CDS"^  T-cells in splenocytes isolated from the animals immunized with Fib-Cp or 
Fib-Lip-Cp (Fig.3.2.9a &b). The data reveals that immunization with Fib-Lip-Cp 
formulation of the antigens results in marked up-regulation of both CD4^ (12.5%) and 
CD8'^  (8.2%) cells when compared to the Fib-Cp form of the vaccine. 
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3.2.10. Protective action of the Cp formulations against C albicans 
infected mice 
Encouraged by the impressive stimulation of both humoral and CMI by the Cp 
formulations a study of their ability to protect mice challenged with 1x10 live C. 
albicans cells was investigated. At the dose administered the fungus was fatal to mice 
in 10 days. Fig. 3.2.10 shows the survival data of mice immunized with various 
formulations of antigens. Fib-Lip-Cp offered most significant protection against the 
i.v. challenge. Mice immunized with other formulations showed markedly lower 
survival rates and no significant difference were observed in the survival profiles of 
animals immunized either with antigen emulsified in IFA or free Cp. On the day 10 
post challenge, all the animals belonging to the control group died, while all the 
animals in the Fib-Lip-Cp groups survived the challenge. Eighty percent animals 
challenged with C. albicans cells survived in Fib-Cp group. 
The prophylactic potential of Fib-Lip-Cp, Lip-Cp and Fib-Cp against C. albicans was 
further investigated by determining the residual fungal load in the blood and various 
vital organs of the mice infected with C. albicans. Animals were sacrificed on day 
five post infection and fungal load in systemic circulation as well as in various vital 
organs (kidney and spleen) was determined. Animals treated with Fib-Lip-Cp, Lip-
Cp and Fib-Cp revealed several fold lower ftingal load in the systemic circulation 
when compared with the free Cp immunized animals (Fig. 3.2.11a). Fungal burden 
was also analyzed in the spleens and kidneys of the animals and it was also found to 
be significantly lower in the animal of the Fib-Lip-Cp, Lip-Cp and Fib-Cp group as 
compared to those treated with Cp (Fig. 3.2.1 lb & c). 
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Fig. 3.2.1. SDS-PAGE of ammonium sulfate fractions of cytosolic proteins of C 
albicans. The cells were lysed, soluble fraction isolated and subjected to stepwise 
ammonium sulfate fractionation as described under Methods. Lane 1 shows the 
molecular weight markers, lanes 2, 3, 4 and 5 shows 0-20%, 20-40%, 40-60% and 60-
80 % ammonium sulphate fractions. 
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Fig. 3.2.2a. Cp-specific IgG titres in the sera of mice immunized with various Cp 
formulations. The sera were analyzed by standard ELISA as described under 
Methods. The data are mean ± standard error of three independent experiments. (Day 
5 post booster, P value; Cp vs. Fib-Lip-Cp<0.05, Cp vs. Lip-Cp <0.05, Cp vs. Fib-
Lip-Cp <0.05, Fib-Cp vs. Fib-Lip-Cp <0.05). Fib-Lip-Cp vs Fib-Cp <0.05, Fib-Lip-
Cp vs IFA <0.05). 
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Fig. 3.2.2b. C albicans Cp-specific IgGl and IgG2a titers in the sera of mice 
immunized with Cp. The formulations were assayed by indirect ELISA. The resuh 
represents the mean ± standard error of three independent experiments. Day 5 post 
booster IgG2a and IgGl levels were measured. P value; Cp vs. FibCp<0.05, Cp vs. 
Lip-Cp <0.01, Cp vs. Fib-Lip-Cp <0.001, Fib-Cp vs. Fib-Lip-Cp <0.05, Fib-Lip-Cp 
vsIFA<0.001). 
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Fig.3.2.3. Post injection DTH response in groups of mice receiving various 
formulations of Cp. The DTH response was determined by measuring foot pad 
swelling in the immunized animals. Data are representative of the mean of three 
independent experiments ± SD values. (P value; Cp vs. Fib-lip-Cp <0.05, Cp vs. Lip-
Cp <0.05, Cp vs. Fib-Lip-Cp <0.001, Fib-Cp vs.Fib-lip-Cp <0.05). 
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Fig.3.2.4. Evaluation of NO production by activated macrophages. NO 
concentration was measured on day 15 after immunization with the Cp formulations. 
Data are representative of three independent experiments ± SD values. (P value; Cp 
vs. Fib-lip-Cp <0.001, Cp vs. Lip-Cp <0.001, Cp vs. Fib-Cp <0.05, Fib-Cp vs. Lip-Cp 
<0.05, Fib-Cp vs. Fib-Lip-Cp <0.05). 
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Fig.3.2.5. Analysis of IFN-y in culture supernatant of lymphocytes belonging to 
the animals immunized with the Cp formulations. IFN-y was measured as 
described under Methods. The values represent the level of cytokine obtained from 
wells pulsed with the optimal antigen concentration (described under methods). Data 
are representative of three independent experiments ± SD values. 
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Fig. 3.2.6. Proliferation of lymphocytes isolated from mice immunized with the 
Cp formulations. Lymphocyte proliferation was measured as described under 
Methods. The values represent the level of stimulation index obtained from wells 
pulsed with the optimal antigen. Data are representative of three independent 
experiments ± SD values. (P values: Cp vs. Fib-Lip-Cps < 0.001; Cp vs. Lip-Cp 
<0.05, IFA vs. Fib-Lip-Cps <0.001, IFA vs Lip-Cp <0.05). 
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Fig. 3.2.7. Analysis of IL-4 release in the cultures of lymphocytes isolated from 
mice immunized with the Cp formulations. The values represent the level of 
cytokine obtained from wells pulsed with the optimal antigen. Data are representative 
of three independent experiments ± SD values (P value; Cp vs. Fib-Lip-CP <0.05.) 
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Fig. 3.2.8a. FACS analysis of lymphocytes isolated from mice immunized with 
Fib-Lip-Cp and Fib-Cp for surface CD80. The lymphocytes were subjected to 
FACS analysis as describe under Methods. The percentage of surface marker CD80 
(B7.1) present on APC population of the animals immunized with Fib-Lip-Cp (A), 
Fib-Cp (B) and Control (C) are shown. 
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Fig.3.2.8b. FACS analysis of lymphocytes isolated from mice immunized with 
Fib-iip-Cp and Fib-Cp for surface CD86. The FACS measurements were made as 
described under Methods. The percentage of surface marker CD86 (B7.2) present on 
APCs population of the animals immunized with Fib-lip-Cp (A); Fib-Cp (B) Control 
(C) are shown. 
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Fig. 3.2.9a. FACS analysis of lymphocytes isolated from mice immunized -with 
Fib-lip-Cp and Fib-Cp for surface CD4^. The percentage of the surface marker 
CD4^ present on the T cell population of the animals immunized with Fib-lip-Cp (A); 
Fib-Cp (B) and Control (C) are shown. 
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Fig. 3.2.9b. FACS analysis of lymphocytes isolated from mice immunized with 
Fib-Lip-Cp and Fib-Cp for the surface CD8\ The percentage of surface marker 
CD8^ present on T population of the animals immunized with Fib-Lip-Cp (A), Fib-Cp 
(B) and Control (C) are shown. 
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Fig. 3.2.10. Protection by immunization using various Cp formulations of mice 
challenged with live C. albicans cells (1x10^). Survival of Fib-Lip-Cp immunized 
animals was significantly greater than that of mice immunized with other 
formulations. Each group contained 10 mice. The figure represents the mean of three 
independent experiments. 
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Fig. 3.2.11a. Fungal buurden in blood of mice immunized using the Cp 
formulations and challenged with live C albicans cells (1 x 10 )^. Fungal burden in 
blood of animals on day 5 and day 30 post challenge is indicated. Value represents 
the mean of three independent experiments ±SD. (day 30 post infection P values; Cp 
vs. Fib-Lip-CP <0.001, Cp vs. Lip-Cp <0.001, Cp vs. Fib-Cp <0.001. 
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Fig. 3.2.11b. Fungal burden in spleen of mice immunized using the Cp 
formulations and challenged with live C. albicans cells. Fungal burden in the 
spleens of the animals on day 5 and 30 post challenge are shown. The figure 
represents the mean of three independent experiments ± SD. (day 30 post infection P 
values; Cp vs. Fib-lip-CP<0.001, Cp vs. Lip-Cp <0.001, Cp vs. Fib-Cp<0.001). 
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Fig. 3.2.11c. Fungal burden in kidneys of mice immunized using the Cp 
formulations and challenged with live C. albicans cells. Fungal burden in the 
kidney of the animals on day 5 and 30 post challenge are indicated. The figure 
represents the mean of three independent experiments ± SD (day 30 post infection P 
values; Cp vs. Fib-lip-CP<0.001, Cp vs. Lip-Cp<0.001, Cp vs. Fib-Cp <0.001). 
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3.3. STUDIES ON THE POTENTIAL OF PLGA MICROSPHERES AND 
FIBRIN CROSSLINKED PLASMA BEADS AS C. albicans ANTIGEN 
DELIVERY SYSTEMS 
In a parallel set of experiments the Cp delivery through PLGA microspheres alone or 
in combination with fibrin crosslinked plasma beads was investigated. The design of 
the experiment was very similar to those in section 3.2 but microsphere entrapped C. 
albicans antigen was investigated in place of the cationic liposomes. The parallel 
sets of experiments were necessitated because of the need to handle large number of 
animals and significant nimiber of samples in each set of experiments. 
3.3.1. Humoral immunity 
The Cp formulations investigated in the set of experiments were Cp emulsified with 
Freund's Incomplete Adjuvant (IFA-Cp), entrapped in PLGA microspheres (PLGA-
Cp), entrapped in fibrin crosslinked plasma beads (Fib-Cp), and that entrapped in 
PLGA microspheres and in turn entrapped in the pbeads (Fib-PLGA-Cp). After the 
administration of the antigen CP formulations antigen-specific antibodies were 
measured in the sera of immunized mice, 10 days after administration of the 
formulafions as well as 5 days after administration of the booster (Fig.3.3.1a). 
Analysis of the sera (1:200 dilutions) revealed most significant upregulation of 
antibody titre in the animals immunized with PLGA-Cp and Fib-PLGA-Cp. The order 
of the level of total antigen specific antibodies in the groups of animals studied was 
Fib-PLGA-Cp>PLGA-Cp>Fib-Cp>IFA-Cp>Cp>PBS. 
Relatively higher total IgG antibody titres were observed on day 5 post-booster in 
the sera in all the animals of all the groups receiving Cp with levels of Fib-PLGA-Cp 
group being highest (^492- 1-2), followed by the PLGA-Cp (^492-0.923) {p < 0.05). 
On the other hand, antibody titre was significantly lower in the animals receiving 
either fi-ee Cp (^ 492 -0.422) or IFA-Cp (^ ^492-0.6). The Fib-Cp combination induced 
high antibody titre (A492=: 0.7) only after day 5 after the administration of the booster. 
The sera collected on day 5 post-booster, were further examined for the isotypes of 
Cp-specific anfibodies. As shown in Fig. 3.3.1b, PLGA-Cp and Fib-PLGA-Cp elicited 
highest IgG2a (J492 -0.744 and ^492= 0.653 respectively), when compared to IgGl 
(^ 492 -0.55 and ^492 -0.594 respectively) isotype (P < 0.05). The IgGl and IgG2a 
92 
antibody litres in the groups immunized with Fib-Cp (A492= 0.522 and 0.433), IFA-Cp 
{A492 ~ 0.308 and 0.350) and Cp (A492~ 0.240 and 0.275) were markedly lower. The 
IgG2a isotype was more abundant than the IgGl in Fib-Cp, PLGA-Cp and Fib-
PLGA-Cp immunized group of animals which is indicative of Thl-type response 
(Mallick et al, 2007) 
3.3.2 DTH response 
Delayed type hypersensitivity, an in vivo manifestation of cell-mediated immune 
response, has direct correlation with the protection of animals against various 
intracellular infections (brucilosis, candidiasis). Immunization of mice with PLGA 
and Fib-PLGA entrapped Cp induced antigen-specific cell-mediated immune 
response, which resulted in accumulation of immune cells at the site of antigen 
administration and in turn in increase in footpad thickness (Fig.3.3.2). As evident 
from the figure, among the various preparations of Cp studied, only PLGA-Cp and 
Fib-PLGA-Cp induced remarkable increase in foot pad thickness (0.63 mm, 0.72 mm 
respectively) in mice, while other Cp formulations were not effective in causing food 
pad thickness alterations. 
3.3.3. NO Production 
Peritoneal macrophages isolated fi-om the immunized mice belonging to various 
groups were cultured in complete RPMI and incubated with Cp (final cone. 
10|xg/well). After incubation, 100 ^l of the supernatant was collected fi-om each well 
and NO production estimated as described in methods. The results suggest that Fib-
PLGA-Cp expressed high level of NO followed by PLGA-Cp and Fib-Cp (Fig. 3.3.3). 
Generation of high NO in response to Fib-PLGA-Cp based immunization suggests 
up regulation of inducible NO synthase (iNOS, N0S2) by Thl associated cytokines 
(Sharma et al, 2005). On day 15 supematant from Fib-PLGA-Cp showed higher 
absorption (A550 =^  0.86) as compared to PLGA-Cp (A550 ~ 0.68) while other 
immunized group produced lower amount of NO. 
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3.3.4. Induction of IFN-Y in immunized mice 
On day 5 post booster splenocytes from various groups of animals were isolated, 
cultured with matching formulation of the antigens and evaluated for the production 
of IFN-y (Fig.3.3.4). Animal immunized with Fib-PLGA-Cp also expressed highest 
level of IFN-y (352 pg/ml), followed closely by PLGA-Cp (270 pg/ml). While 
production of IFN-y was moderate in splenocytes stimulated by Fib-Cp and IFA-Cp, 
the levels were higher than those detected in the splenocyte cultures incubated with 
free form of the Cp. Very little IFN-y was detectable in the cultures derived from 
animals immunized with PBS alone (no antigen). 
3.3.5. Production of IL-4 
On day 5 post boosters, the splenocytes isolated from various groups of animals were 
cultured with matching formulation of the antigen and the cultures were analyzed for 
the production of IL-4, a member of type 2 cytokine family. In this case Fib-PLGA-
Cp and PLGA-Cp cultures revealed low levels of IL-4 (123 pg/ml and 133 pg/ml 
respectively) by the stimulated cells when compared to those incubated with IFA-Cp 
or free Cp (Fig. 3.3.5). Among other forms of antigen preparations examined, only 
IFA-Cp induced higher level of IL-4 than that produced by free form of Cp. 
3.3.6. Lymphocyte proliferation 
The potential of various formulations of Cp on the proliferation of antigen-specific 
lymphocytes was also investigated. In these experiments also mice immunized with 
Fib-PLGA-Cp and PLGA-Cp revealed significantly higher lymphocyte proliferation 
when compared with those obtained from animals treated with IFA-Cp or free form of 
Cp (Fig. 3.3.6). The splenocyte responsiveness to antigen was dose-dependent and 
increased with the antigen concentration used. However the figure only shows 
maximum proliferation obtained in various groups (20 ug Cp/well. Control groups, 
containing T lymphocytes obtained either from animals immunized with free form of 
antigen or PBS, induced only marginal T cell proliferation. 
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3.3.7. Surface expression of CD80 & CD86 
Flow cytometric analysis was carried out to evaluate the quantum of expression of 
CD80 & CD86 on the surface of splenocytes (antigen presenting cells, APCs) isolated 
from groups of animals immunized with various formulations of Cp (Fig.3.3.7a & b). 
The APCs isolated from animals immunized with Fib-PLGA-Cp were superior in 
expression of both CD80 (11.74) and CD86 (16.88) on their surface as compared to 
other groups. In contrast, APCs isolated from animals immunized with PLGA-Cp 
expressed relatively fewer CD80 (8.14) and CD86 (8.88) on their surface. 
3.3.8. Surface Expression of CD4* and CD8^ 
Flow cytometric analysis was also undertaken to evaluate the expression of CD4^ and 
CD8^ T cells in the splenocytes isolated from the animals immunized with Fib-Cp, 
PLGA-Cp and Fib-PLGA-Cp (Fig.3.3.8a, b). T cell isolated from animal immunized 
with Fib-PLGA-Cp showed significantly higher expression of both CD4"^  (15%) and 
CD8'*^  (8.5%) as compared to the PLGA-Cp and Fib-Cp formulations. Immunization 
with PLGA-Cp and Fib-Cp induced only 7.9% and 6.8% CD4^ T cells and 8.5% and 
6.7% CD8^ T cells. 
3.3.9. Protection against C. albicans infection in Balb/c mice 
Vaccine potential of Fib-PLGA-Cp and PLGA-Cp was evaluated against 
experimental candidiasis in mice challenged with live C. albicans. Groups of mice 
were administered PBS; Cp alone, IFA-Cp, Fib-Cp, PLGA-Cp or Fib-PLGA-Cp as 
described earlier. The mice were immunized with a total of two doses of Cp 
formulations subcutaneously (100 ng/animal on day 0 and 60 ng/animal on day 14) 
and subsequently challenged i.v. with live C. albicans cells (Ix 10^ cells per animal) 
in order to induce disseminated candidiasis. The data on day 15 post infection 
showed almost 90, 80 and 60 percent survival of animals immunized with Fib-PLGA-
Cp, PLGA-Cp and Fib-Cp respectively. No animal survived in the control groups 
beyond day 15 post infection (Fig.3.3.9). On the day 30 post challenge with live C. 
albicans cells, the survival rate of animals immunized with Fib-PLGA-Cp was 60%, 
while it was 50% for PLGA-Cp and only 40% in case of Fib-Cp. Only 20 and 30 
percent of the animals survived in groups immunized with free Cp and IFA-Cp. 
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The prophylactic potential of Fib-PLGA-Cp, PLGA-Cp and Fib-Cp against systemic 
candidiasis was also further investigated by determining the residual fungal load in 
various vital organs of animals challenged with live C albicans cells. The animals 
were sacrificed on day 5 post challenge to determine the fungal load in systemic 
circulation as well as in various vital organs. The data suggest that the animals treated 
with Fib-PLGA-Cp, PLGA-Cp and Fib-Cp have several fold lower fungal load in the 
systemic circulation when compared with free Cp immunized animals (Fig. 3.3.10a). 
The fungal load in the systemic circulation was in agreement with the severity of 
infection. The fungal burden in the spleen and kidney was also lower in the animal of 
the Fib-PLGA, PLGA-Cp and Fib-Cp groups as compared to mice treated with free 
Cp (Fig. 3.3.11b & c). Animals that survived up to day 30 were also screened for 
residual fungal load in the various vital organs. The animals which were immunized 
with Fib-PLGA-Cp, PLGA-Cp and Fib-Cp showed far fewer CFU both in the in 
spleen and kidneys as compared to the groups of animals immunized with free Cp. 
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Fig.3.3.1a. Cp speciflc IgG titres in the sera of mice immunized with various 
formulations of Cp. Animals were immunized either with free Cp, IFA-Cp, Fib-Cp, 
PLGA-Cp or Fib-PLGA-Cp. IgG concentrations in the sera of the animals were 
analyzed by ELISA as detailed under methods. The data are mean ± standard error of 
three independent experiments. (P value; 5 the post booster, Cp vs Fib-PLGA-CP 
<0.001, Cp vs PLGA-Cp <0.05, Cp vs Fib-Cp <0.05, IFA vs Fib-PLGA-Cp <0.05, 
Fib-Cp vs Fib-PLGA-Cp <0.05). 
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Fig.3.3.1b. C albicans Cp-specific IgGl and IgG2a titers in the sera of mice 
immunized with various Cp formulations. The IgG subclasses were quantitated by 
indirect ELISA as described under Methods. Values represent the mean ± standard 
error of three independent experiments. (For isotype IgG2a, P values; Cp vs Fib-
PLGA-CP <0.001, Cp vs PLGA-Cp <0.05, Cp vs Fib-Cp <0.05, IFA vs Fib-PLGA-
Cp <0.001, Fib-Cp vs Fib-PLGA-Cp<0.001). 
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Fig.3.3.2 Post injection DTH response in groups of mice receiving various 
formulations of Cp. The DTH response was determined by measuring footpad 
thickness in the animals immunized with PBS, free Cp, IFA-Cp, Fib-Cp, PLGA-Cp or 
Fib-PLGA-Cp. Data are representative of three independent experiments ± SD values. 
(P values; Cp vs Fib-PLGA-CP <0.001, Cp vs PLGA-Cp <0.001, Cp vs Fib-Cp <0.05, 
IFA vs Fib-PLGA-Cp <0.001, Fib-Cp vs Fib-PLGA-Cp<0.05). 
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Fig.3.3.3 Evaluation of NO production by activated macrophages. NO 
concentration was measured on day 15 after Cp immunization using various Cp 
formulations and controls. Data are representative of three independent experiments ± 
SD values. (P values; Cp vs Fib-PLGA-CP <0.001, Cp vs PLGA-Cp <0.001, Cp vs 
Fib-Cp <0.05, IFA vs Fib-PLGA-Cp <0.001, Fib-Cp vs Fib-PLGA-Cp <0.05). 
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Fig.3.3.4. Analysis of the IFN-y in culture supernatant of lymphocytes of animals 
immunized with the Cp formulations. IFN-y was measured as described. Values 
represent the levels of the cytokine obtained from wells pulsed with the optimal 
antigen as described under methods. Data are representative of three independent 
experiments ± SD values. (P value; Cp vs Fib-PLGA-CP <0.001, Cp vs PLGA-Cp 
<0.001, Cp vs Fib-Cp <0.05, IFA vs Fib-PLGA-Cp <0.001, Fib-Cp vs Fib-PLGA-
Cp<0.05) 
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Fig.3.3.5. Analysis of IL-4 release in culture supernatants of lymphocytes isolated 
from mice immunized with various formulations of Cp. IL-4 was measured as 
described under Methods. Values represent the level of cytokine obtained from wells 
pulsed with the optimal antigen. Data are mean of three independent experiments ± 
SD values (P value; Cp vs Fib-PLGA-CP <0.05) 
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Fig.3.3.6. Lymphocyte proliferation assay. Proliferation of lymphocytes isolated 
from mice immunized with various formulations of Cp was studied. Values represent 
the stimulation index from the wells containing the lymphocytes pulsed with the 
optimal antigen concentration as described under methods. Values are mean of three 
independent experiments ± SD values. (P values; Cp vs Fib-PLGA-CP <0.001, Cp vs 
PLGA-Cp <0.05, Cp vs Fib-Cp <0.05, IFA vs Fib-PLGA-Cp <0.001, Fib-Cp vs Fib-
PLGA-Cp <0.05). 
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F^33,7a. Flow cytometric analysis of CD80 marker on surface of APCs. 
Lymphocytes isolated from mice immunized with Fib-PLGA-Cp (A>, PLGA-€> (B>, 
Fib-Cp (C) and Control (D) were subjected to flow cytometric analysis as described 
under methods. The percentage of surface marker CD80 (B7.}) present on APCs 
population of the immunized animals. Red fluorescence shows the ceils which are 
bound with fluoresc€»t tag with respective marker antibodies whfJe g^een colof shows 
unstained and dead celts. 
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Fig.3.3.7b. Flow cytometric analysis of CD86 on the surface of APCs 
Lymphocytes isolated from mice immunized with various formulations of Cp were 
analyzed for CD86 as described under methods. For other derails refer to legend to 
figure 33 Ja 
104 
I 
o 
c 
o 
n 
n 10 
3 
r» 
<0 
1Ue4-
10e3-
10e2-
10e1-
10eO-
1C 
B 
leO 
* • 
; L 
• • 
• 
wM 
•• 
.-• 
7.9% •• 
• '•* 'l 
'M E3mt 
^ J f ^ ^ R 
lOel 10 te2 10e3 
\ -
10< 
1Ue4-| 
10e3-
10e2-
10e1-
10eO-
A 
• ! - l - f . f f * 
• • 
• 
T ' • 
•• 
• 
9 
• ^l 
15% >.^-
\S^i»-^K: 
^^^^^" 
• 
• 
1Ue4n . ^ , . lUe4 
10e3 
10e2-
lOel 
10eO-W 
6.84% 
10e3-
10e2 
lOelH 
1( 
0 3 8 % 
> •/*•• 
lOeO l O e l 10e2 10e3 10e4 lOeO lOel 10e2 10e3 10e4 
> Forward Scattered > 
FigJJ.8a.FIow cytometric analysis of surface marker CD4* on the T cell. The 
cell surface marker CD4^ was studied as described under methods. For other details 
please refer to legend to Fig. 8a. 
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Fig.3.3.9. Protection by immunization with Cp formulations in mice challenged 
with live C. albicans cells. Survival of animals immunized with various Cp 
formulations was studied. Each group contained 10 mice. The figure represents the 
data based on three independent experiments. 
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Fig.3.3.10a. Fungal burden in blood of mice immunized with various Cp 
formulations and challenged with 1x10* live C albicans cells. Value represents the 
mean of three independent experiments ±SD. (day 30 post infection P values; Cp vs. 
Fib-PLGA-CP <0.p01, Cp vs. PLGA-Cp <0.001, Cp vs. Fib-Cp <0.001. 
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Fig.3.3.10b. Fungal burden in spleen of mice immunized with various Cp 
formulations of Cp and challenged with live C. albicans cells. The figure 
represents the mean of three independent experiments ± SD (day 30 post infection P 
values: Cp vs. Fib-PLGA-CP<0.001, Cp vs. PLGA-Cp <0.001, Cp vs. Fib-Cp <0.001. 
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Fig.3.3.10c. Fungal burden in kidney of mice immunized with various Cp 
formulations and challenged with 1x10* live C. albicans cells. The figure 
represents the mean of three independent experiments ±SD. (day 30 post infection P 
values; Cp vs. Fib-PLGA-CP <0.001, Cp vs. PLGA-Cp <0.001, Cp vs. Fib-Cp 
<0.001. 
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4.0. DISCUSSION 
The combination of purified fibrinogen and bovine thrombin was first used in 1944 to 
enhance the adhesion of skin grafts in soldiers with severe bum injuries (Tidrick and 
Warner, 1944). Observed allergic reactions in patients receiving the bovine protein 
and hypothetical risk of transmission of infectious agents like those causing bovine 
spongiform encephalitis (Radosevich et al, 1997), lead to the use of recombinant 
human thrombin in place of the bovine enzyme. Allergic reactions to subtype human 
components of the glue have also been reported (Suzuki et al, 1994; Baumann et al., 
1993; Nakamura et al, 1991; Van der et al, 1991). Although a number of commercial 
sealants are currently available that use fibrinogen, factor XIII and thrombin of human 
origin, the risks of infection by thermostable pathogens (Saldanha et al, 1996) and 
viral diseases like hepatitis and AIDS persist (Jackson, 2001). Commercial sealants 
and the preparations using autologous components however continue to be 
investigated and used for a variety of applications. The outstanding advantages of the 
plasma beads described in this study are non-requirement of any exogenous 
component like thrombin with potential to cause immunological complications, 
convenience of using autologous plasma in the preparation of beads and simplicity of 
the procedure that permits the bead preparation with facilities available in most 
hospitals. 
Clotting of plasma was catalyzed by the endogenous transglutaminase that was 
apparently activated in presence of CaCla. High concentrations of calcium were 
required also due to presence of EDTA that was added to blood to prevent clotting. 
Since no other additions were made to the plasma, we believe that the nature of clot 
formed in presence of all plasma constituents is very similar to that formed during 
blood clotting after injury, except for the lack of cellular fractions. CaCb, the only 
addition made, could be conveniently sterilized and entire procedure of bead 
formation accomplished with autologous plasma minimizing the risks of infection and 
allergic reactions inherent while using purified fibrinogen and thrombin as discussed 
earlier. 
I l l 
Uniformity and dimensions of the beads could be controlled with remarkable 
accuracy (Fig.3.1.2; Table V), because measured quantities of the calcium enriched 
plasma were transferred on to the slides with the help of a pipette. It is possible to 
prepare large number of beads rapidly with help of multichanneled pipettes. While 
larger sized beads apparently retain the entrapped pharmaceuticals more effectively 
(Fig.3.1.3.), their introduction in the body necessitates the use of large sized needle or 
even a small excision. 
SDS PAGE of the plasma beads showed a protein profile essentially similar to that of 
the rabbit plasma (Fig.3.1.4). This suggests that the albumin and other plasma proteins 
were mostly physically trapped in the fibrin network rather than being crosslinked 
during the clot formation. Increase in staining in the region corresponding to 97 kDa 
and at that > 200 kDa suggests continuation of crosslinking of the bead proteins 
during incubation. Some proteolysis is also evident in the protein profile of beads 
incubated for five days in phosphate buffered saline as decrease in intensity of the 
albumin band and appearance of those of 23-27 kDa. However the beads are 
significantly leaky to proteins and part of the observed decrease in albumin 
concentration could result fi-om its release from the beads (data not included). Beads 
prepared from purified thrombin are also leaky to proteins, and the diffusion 
coefficient of the entrapped molecules was found to be a function of the molecular 
size (Ho et al, 1995). Marked crosslinking of the bead protein, as anticipated 
appeared, when the beads were exposed increasing concentration of the bifunctional 
glutaraldehyde (Fig.3.1.5). 
Earlier studies on release of entrapped soluble antibiotics from fibrin clot showed that 
they are nearly completely released in 72 (Redl et al, 1983) or 96 hours (Greco et al, 
1991). Under controlled conditions however, even water soluble antibiotics such as 
gentamycin and ciprofloxacin are released from fibrin matrices over 5-7 days, 
although a major portion of the entrapped antibiotic was released in the first two days 
(Marone et al, 1999). Drug release from the fibrin gels in vitro is however strongly 
dependent upon the hydrophobicity of the drugs as well as their ability to bind to the 
matrix components. The entrapped soluble antibiotic and drugs are believed to diffuse 
out of the fibrin matrix readily (Boyce et al, 1994), while the release of insoluble and 
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very large molecular weight substances appears to occur by diffusion and additionally 
due to the degradation of the fibrin matrix (Woolverton et al, 2001). 
When poorly soluble antibiotics are entrapped in fibrin matrix at concentrations 
greater than their solubility, they are deposited as heterogeneously sized crystals and 
released into the medium gradually (Woolverton et al, 1999). In a more recent study 
h has been shown that the release of entrapped molecules is also hampered by their 
binding to the matrix proteins (Gorodetsky et al, 2005), or those entrapped within the 
matrix during the formation fibrin net works (Wong et al, 2003). Apparently 
entrapment of large amounts of albumin in the plasma beads that occurs during the 
preparation of plasma beads retard the release of tetracycline and amphotericin B, 
that have marked affinity for the plasma protein (Fig. 3.1.8 and 3.1.9). 
The relative rates of release of antibiotics from the plasma beads were most rapid in 
case of daunorubicin, followed by the comparatively less soluble tetracycline 
(Fig.3.1.8). Among three different model drugs, the release of amphotericin B 
(Fig.3.1.9) was slowest. Tetracycline binds to BSA and it has been shown that there 
exist one high and six low affinity binding sites for the antibiotic on the protein (Alam 
et al, 2004). Amphotericin B is known to bind strongly to albumin and other plasma 
proteins (Brajtburg et al, 1984; Bekersky et al, 2002). 
While amphotericin B is the most effective against candidasis and other fungal 
infections (Bodey, 1977), its use is limited due to its high toxicity and side effects 
(Edwards et al, 1978; Gondal et al, 1989). Toxicity of amphotericin B has been 
decreased remarkably using mutilamellar (Graybill et al, 1982) or unilamellar 
liposomes (Gondal et al, 1989) that release the drug gradually. The remarkably slow 
release of the antifungal from plasma beads (Fig.3.1.9), especially those crosslinked 
with glutaraldehyde suggests the usefulness of the plasma bead based amphotericin B 
in its sustained delivery. Glutaraldehyde treatment by introducing additional 
crosslinking among the matrix proteins decreases the porosity and degradability of the 
fibrin gels (Wang et al, 2008). It is also likely that glutaraldehyde treatment may lead 
to crosslinking of the amino group containing drugs like daunorubicin and 
tetracycline to the matrix proteins. Such crosslinking may not however inactivate the 
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drugs, since daunorubicin conjugated to erythrocyte ghosts with glutaraldehyde 
showed superior cytotoxic activity both in vivo and in vitro on human osteosarcoma 
cells (CRL-1427) and on mouse leukemia cells (P388D 1) in vitro (Gaudreault et ai, 
1989). Although glutaraldehyde was highly effective in lowering the leakage of drugs 
from the plasma beads, its cytotoxic nature may be a limitation in its use for in vivo 
studies (Sung et al, 2003). More biocompatible and less toxic crosslinking agents are 
however available (Sell et al, 2008) and can be exploited for obtaining plasma beads 
with desirable kinetic characteristics. 
The plasma beads even without additional crosslinking remained intact after seven 
days of incubation in phosphate buffered saline (Fig.3.1.4). Degradation of fibrin 
supports is significant in vivo or when challenged with proteases like plasmin in vitro 
and inclusion of protease inhibitors like aprotinin confers recalcitrance (Yoshida et 
al, 2000). While some of the plasma proteases including those released during 
clotting may have been eliminated during extensive washing of the beads, some 
apparently remain as evident from the continued proteolysis evident up to five day 
incubation in the saline (Fig. 3.1.4). Our experiments suggest that inclusion of 
aprotinin has only a small effect in restricting the release of proteins/drugs from the 
plasma beads (unpublished observation). Since a large number of protease inhibitors 
exist in plasma (Clark, 2003) and are likely to be entrapped during the formation of 
plasma beads, they apparently restrict bead proteolysis in absence of added inhibitors. 
The preliminary study on analysis of serum concentrations of cefotaxime after the 
administration of the free or plasma bead entrapped antibiotic or indeed suggest 
gradual release of the antibiotic in systemic circulation. While the plasma levels of 
cefotaxime fell rapidly from 5.6 ng/ml observed at 4 hours after administration to 
undetectable levels, plasma of the animals receiving plasma bead entrapped drug 
reached a peak value in 24 hours declined gradually and 0.6 ng/ml antibiotic was 
present in the plasma after 136 hours. In fact the levels at 108 and 136 hours were 
similar suggesting the attainment of a kind of plateau. It is not unlikely that local 
levels of the antibiotic remain far higher for far longer time in absence of adequate 
spill over to the systemic circulation making the drug delivery using plasma beads 
effective in the treatment of local infections (Woolverton et al, 2001). 
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It is interesting to note that more crude preparations such cryoprecipitates made from 
patient's own blood appear to have better utility especially in wound healing than the 
highly purified commercial preparations. This is presumably related to additional 
blood derived products in the former including fibronectin, fibroblast growth factor, 
protease inhibitors, cytokines including transforming growth factor beta (TGF-P) and 
platelet-derived growth factor (PDGF) (Clark, 2003). It is also interesting that the first 
report on the establishment of surgical haemostasis involved the use of dried plasma 
as a source of fibrinogen and fibrin fleece (Bergel, 1909). 
Finally, in the present study we propose a simple and straight forward strategy to 
prepare plasma clots in the beaded form for sustained and slow release of entrapped 
molecules. The beads have potential in slow delivery of various drug molecules over 
extended time period. The beads can also be used as vehicles for protein, plasmids 
(Christman et al, 2005) and other macromolecules, in order to develop slow release 
DNA/antigen vaccines. The most attractive feature is that plasma bead based delivery 
system can be prepared from patient's own blood plasma alone thus rule out any risk 
of untoward immune response (because of alloreactive thrombin and other clotting 
components) in host upon its subsequent administration to cure the disease. 
Pathogen specific antibodies play a major role in containing the establishment of 
various pathogens for their establishment in the host. In fact, antibodies protect the 
host against invading pathogens right from the entry point itself. However, the 
protective immimity against intracellular pathogen is far more complicated as such 
organisms adapt intracellular parasitism to avoid antibody recognition. The role of 
immunological response against containment of dimorphic fiangi, such as C. albicans, 
continues to remain a contentious issue. While several researchers contend that the 
specific antibodies may be protective in experimental dissiminated candidiasis (Kirby 
and Gregoriadis, 1984), other lines of evidences mitilate against protective ftinction of 
pathogen-specific antibodies in containing the infection (Han and Cutler, 1995). The 
controversy can be attributed to the ability of the fiingus to reversibly switch between 
unicellular yeast and filamentous form in the infected host (Wajner et al, 1996). 
Although controversy among the researchers on the role of antibody protection has 
not been resolved fiilly, recent evidence suggest that antibodies with defined 
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specificities offer various level of protection both against systemic and mucosal 
candidiasis (De Bemardis et al, 1997; Han et al, 1998; Han et al, 1999). 
Nevertheless, innate immunity as well as cell-mediated immunity are considered 
equally important lines of defense against candidiasis (Levitz, 1992). Casadevall et 
al. (1998) suggested that multiple arms of the immune system, such as innate, cell-
mediated and antibody-mediated processes work synergistically and modulate each 
other with the final goal of combating candidiasis. 
While immunization of animals using exogenous antigen generally leads to the 
generation of antigen-specific antibodies, activation of cytotoxic T lymphocytes is far 
more problematic. It is now well recognized that encapsulation in the liposome 
protect the antigen from rapid degradation and remarkably extends their availability 
for immunorecognition. Taking also into consideration the well-studied slow and 
sustained delivery of entrapped substances from Fibrin matrices, one can speculate 
that the antigen entrapped in the dual slow release system, comprising liposomes amd 
fibrin net work, will be effectively delivered to the APCs. Sustained release 
accompanied by the accumulation of the antigen in the vicinity of APCs is likely to 
enforce antigen to follow MHC-I processing and presentation and ultimately elicit 
cytotoxic CD%^ and T lymphocyte response (Lilic et al, 1996). 
In the present study we used partially purified cytosolic fraction of Candida proteins 
(Cp) and evaluated their immuno-prophylactic activity against experimental 
candidiasis. As the yeast and filamentous forms of C. albicans differ strikingly in 
morphology but contain several common cytosolic proteins (Odds, 1998), we opted to 
use 60-80 ammonium sulphate fi-action of cytosolic proteins (Fig. 3.2.1) as candidate 
antigen in the study. It was envisaged that use of multiple antigens can possibly 
provoke both humoral and cell mediated immunity and be effective against the yeast 
and filamentous forms of C. albicans. 
The fibrin bead-entrapped Cp vaccine was found to evoke highly favourable immune 
response in the immunized mice. Fib-Cp was effective in eliciting remarkable 
production of IgG, on the day 10 and more markedly on 5 day after administration of 
the booster. The total IgG level were higher than in the groups receiving free or IFA 
emulsified Cp, suggesting the advantage of entrapment of the antigen in the fibrin 
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matrix (Fig.3.2.2a). Usefulness of entrapment of liposome containing 
pharmaceuticals, including various proteins, in the fibrin gels in extending their 
release have been highlighted in several studies (Senderoff e^  al., 1996; Chang et al, 
2006; Wang et al, 2008). To fUrther increase the efficacy of Cp, we prepared 
liposome-encapsulated Cp formulations that were further intercalated in fibrin beads 
to develop dual composite antigen delivery system. Apparently, the Cp release from 
the Fib-Lip-Cp is slow and sustained. The results indeed suggest that entrapment in 
the double entrapment delivery system slow down the release of free Cp and hence 
more effectively than that encapsulated in the liposomes. The levels of lgG2a were 
slightly higher as compared to those of IgGl in all the mice receiving the antigen but 
the difference was more marked in the Fib-Lip-Cp group. This suggests strong 
stimulation of B lymphocytes for the expression of Cp specific antibodies IgGl and 
IgG2a isotypes. Remarkably a clear cell-mediated response was also observed in 
animals, which were immunized with Fib-Lip-Cp, but not in the control groups 
including those immunized with IFA-Cp and free Cp (Fig.3.2.2b). In addition, DTH 
immune responses were remarkably high in the animals immunized with Fib-Lip-Cp 
formulation which also elicited strong T cell proliferation. (Fig.3.2.3) 
A number of antimicrobial and cytotoxic substances produced by activated 
macrophages can destroy both phagocytosed micro-organism as well as intracellular 
pathogens with equal propensity. In fact, activated phagocytes produce a number of 
reactive oxygen intermediates and reactive nitrogen intermediates that have potent 
antimicrobial activity. The so called "respiratory bursf of activated macrophages 
catalyzes the reduction of oxygen to superoxide anion and some times even to 
hypochloride as well. Besides activated macrophages begin to express high levels of 
nitric oxide synthase (NOS), an enzyme that oxidizes L-arginine to yield L-
citrullinase and nitric oxide. The later has potent antimicrobial activity. Both 
superoxide as well as NO can form a deadly combination to fight pathogens of fungal 
and bacterial origin. 
Mouse macrophages exposed to IFN-y in combination with LPS, TNF or IL-1 express 
high out put of nitric oxide synthase, that catalyze the production of NO that is highly 
toxic to the invading microorganism (Abbas et al, 1998). The remarkably high levels 
of NO observed in the macrophages cultures derived from Fib-Lip-Cp groups 
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(Fig.3.2.4) incubated with the antigen suggests high activity of the NO synthase in the 
cells. Boosting with the antigen resulted in enhancing the ability of the macrophages 
to NO producing activity in Fib-Lip-Cp, Lip-Cp and Fib-Cp in that order. 
Research on the immunopathology of Candida infection has facilitated in depth 
understanding of several aspects of regulation in the immune system. Intracellular 
phase of parasite in macrophages avoid direct interaction with the pathogen specific 
antibodies, propagated by the immune system of the host to eliminate them from 
systemic circulation. It has been observed that protective immunization against 
Candida thriving inside the hostile environment of the host cells is mediated 
essentially through cellular immune responses (Liebana et al, 1999). Cytokines 
produce by the Thl cells (IL-2 and IFN-y) activate macrophages to kill the parasites 
where as those secreted by the Th2 cells (IL-4, IL-5, and IL-10) also suppress disease 
(Agrewala and Wilkinson, 1998). Surprisingly, protective immunity against visceral 
systemic candidiasisis is even more complex and mere differential production of Thl 
and Th2 cytokines that does not control the vaccine induce rate of cure (Cummings et 
al, 2010). It is well established that CD4"^  T helper and CD8^ cytotoxic phenotype 
may be influenced by cytokine milieu, the differential expression of co-stimulatory 
molecules, antigen dose, difference in affinity at the TCR-peptide-MHC interface and 
adjuvants (Agrewala et al, 1996; Agrewala et al, 1998; Braciale et al, 1987; Liebana 
et al, 1999). The induction of cell-mediated immunity (CMI) to protein antigen is 
depend on the activation of CD4^, MHC class 11 (T-helper cells) and CD8^ MHC 
class I (cytotoxic T cells) restricted T cells (Braciale et al, 1987; Liebana et al, 1999; 
Unanue et al, 1987). T-helper cells (Th) facilitate cytotoxic T cell (CTL) and B cell 
responses, and help in the production of class switching and memory responses. T 
lymphocytes are of strategic importance in killing of the cells infected with 
intracellular pathogens and also towards surveillance mechanisms against cancer 
cells. In the previous studies we as well as other research groups demonstrated that 
liposomes mediated delivery of antigen can elicite both cell mediated as well as 
humoral immunity simultaneously (Owais et al, 2000; Ahmad et al, 2001). This led 
us to believe that incorporation of liposomized antigen in the fibrin would be able to 
induce both cell- mediated as well as humoral immunity. Incidentally, both the arms 
of immune system are reckoned to actively participate in the elimination of Candida 
infection fi-om cystemic circulation (Levitz, 1992; Huffiiagle et al, 1994). Hence, we 
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considered it worthwhile to exploit the proposed delivery system for elimination of 
Candida species from systemic circulation. 
The Fib-Lip-Cp-mediated antigen delivery also ensued highest up-regulation of Type 
I cytokines that facilitate induction of CD8^ T lymphocyte response. Thus, 
immimization with Fib-Lip-Cp formulation induces IFN-y cytokines to level higher 
than those by Lip-Cp and Fib-Cp, immunization (Fig.3.2.5). While the later groups 
led to the production of IL-4 mainly, Fib-Lip-Cp in fact down regulated the IL-4 
production (Fig.3.2.6). IL-4 produced by Th2 of helper T lymphocytes inhibits 
macrophage activation. IFN-y is known to inhibit IL-4 mediated B cell switching to 
IgE (Abbas e/Of/., 1998). 
Beside Thl/Th2 polarization in favor of cell-mediated immune response, delivery of 
antigens to the cytosol of the antigen presenting cell ensues its processing and 
presentation along with MHC class I pathway and thereby facilitates induction of 
antigen specific CTL response in the immunized animals (Hung et al, 2006). The 
Thl/Th2 polarization in favour of Type-1 cytokines also explains isotype switching 
evident in the sera of animals immunized with Fib-Lip-Cp formulations. 
Results from this study substantiate the earlier observations that both liposome and 
microsphere based antigen delivery system interact with APCs by endocytic mode 
mainly resulting in the induction of CD4^ T cell responses (Owais and Gupta, 2000). 
In contrast, the use of fibrin based liposomised or microsphere encapsulated antigen 
lead to the generation of both Th-1 and Th-2 cells. It is primarily because of the fact 
that the optimum activation of Th cells requires not only TCR occupancy by 
presented MHC-antigens complex, but also a set of another co-stimulatory signals 
provided by APCs (Agrewala and Wilkinson, 1998). Expression of CD80 and CD86 
in (Fig. 3.2.8a and 3.2.8b) this regard play a major role in providing co-stimulation to 
T cells, leading to their proliferation, cytokine production, and development of 
effector functions. Higher expression of CD80 and CD86 as a result of fibrin-based 
vaccination again suggests enhancement in the antigen presentation to macrophages 
leading to the expansion of Th cells (Agrewala et al, 1996). 
The higher populations of CD4^ and CD8^ cells (Fig. 3.2.9a and 3.2.9b) in the 
animals immunized with Fib-Lip-Cp formulations clearly demonstrate the efficacy of 
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groups in T cell proliferation. The longer availability of antigen in host system, we 
believe, facilitates greater interaction of the antigen with APCs, which in turn assist 
their processing and presentation. The antigen presented on the surface of APCs 
activate CD4 and CDS cells and in turn result in their maximum proliferation and 
differentiation. 
The protection studies demonstrate remarkable survival rate of animals which 
were immunized with Fib-Lip-Cp, as compared to the controls and those receiving 
free antigens. Fib-Lip-Cp also offered superior protection when compared with the 
groups receiving the Lip-Cp preparations (Fig.3.2.10), supporting the superiority of 
the Fib-Lip based dual antigen delivery system. The data of the present study 
substantiates this assumption that Fib-Lip-Cp based vaccination successfully elicits 
desired CTL (cell mediated) and antibody (humoral) response. The generated 
antibodies as well as cytotoxic T lymphocytes apparently recognize both unicellular 
yeast as well as filamentous intracellular form of C. albicans and obliterate infection 
completely by killing both fungal forms in comparison, immunization with both Lip-
Cp or Fib-Cp activated relatively low level of humoral and CTL immune response. It 
is likely that Lip-Cp and Fib-Cp based vaccines are effective against the yeast form of 
invading C albicans, while the filamentous form escape the antibody mediated killing 
by adapting intracellular parasitism in the cytosol of antigen presenting cells (Owais 
and Gupta, 2000). The surviving fiingal cells ultimately lead to recurrence of infection 
and subsequent death of animals. The protection offered by various Cp formulations 
against C. albicans infection was further substantiated by measuring the fungal 
burden in systemic circulation, spleen and kidneys of the immunized mice on day 5 
and 30 post infection with C albicans cells. We hypothesized that immunization with 
Fib-Lip-Cp leads to the generation of antibodies which subdue virulence of infection 
and delay the establishment of the infection. The remarkable reduction in fungal load 
in various vital organs observed the initial phase of exposure to infection by C 
albicans in Fib-Lip-Cp treated animals apparently supports our hypothesis (Fig. 
3.2.10a, 3.2.10b and 3.2.10c). 
Since protective immunity against C. albicans infection needs to address both the 
yeast as well as hyphal form of the pathogen, the presence of hyphae form in the 
cytosol of antigen presenting cells need an immunization protocol which can eradicate 
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intracellular pathogens, we used Fib-Lip-Cp based carrier system to target pathogen 
specific humoral as well as cell mediated immune responses. 
The data of present study suggests that exogenous antigen delivery can be 
manipulated for the simultaneous presentation with MHC-1 as well as MHC-Il 
processing and presentation pathways by facilitating their slow in vivo delivery and 
thereby induce both humoral as well as cell mediated immunity. 
Finally, we conclude that the fibrin mesh based liposomal vaccine successfully 
protects mice against C. albicans and may pave the way for its emergence as a model 
system for use against other infection. 
The results of the study show that: 
a) C albicans partially purified antigen (Cp) encapsulated in cationic liposomes 
and entrapped in Fibrin, mediates both humoral and cellular immune response 
against entrapped C. albicans antigen, 
b). Administration of C. albicans antigen bearing fibrin-liposomes preparation 
induces strong CD4" /^CD8^ T lymphocyte inmiune responses, 
c). Besides CD8"^  T lymphocyte induction, fibrin-liposomes encapsulated C. 
albicans antigens activate B lymphocytes for IgG2a/IgGl antibody 
production, 
d). Immunization with liposomes encapsulated and fibrin entrapped antigen 
imparts protection against C. albicans infection, 
e). Fibrin-liposomes-based vaccines can suppress virulence of C. albicans. 
As already mentioned, no vaccine is currently available for human mycoses although 
there exists an urgent need to develop measures of prophylactic immunoprevention 
against the fungal pathogens. The conventional vaccines (attenuated) containing live, 
replicating organisms are associated with an inherent risk of infection because they 
tend to revert and causes infection. Heat killed vaccine, on the other hand require 
boosters to augment the immune cells (Ingolotti et al, 2010). Subunit vaccines 
presently available in the market are expensive and labor involved in the purification 
process as well as immunogenic substances present as impurities constitute a 
hindrance in the development of such vaccines. 
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Antigens that induce resistance to systemic candidiasis induce cell wall components 
protein and cytosolic soluble proteins (Baghian et al, 1989: Jensen et al, 1993: 
Jones-Carson et al, 1990). The data suggested that immunization with partially 
purified cytosolic protein of C. albicans entrapped in PLGA and PLGA entrapped in 
the fibrin beads imparts high level of protection against systemic challenge with a 
virulent strain of C. albicans. While the animal immunized with free antigen or free 
antigen bearing fibrin crosslinked plasma beads failed to eliminate pathogen 
significantly. 
Animals immunized with the Fib-PLGA-Cp and PLGA-Cps shows the higher 
secretion of IgG (Fig.3.31a.) and the isotypes (Fig. 3.3.1b) than the animals 
immunized with the IFA-Cp or free Cp. 
As shown previously liposome encapsulated antigen imparts high DTH response than 
free Cp in immunized animals, PLGA entrapped in fibrin beads and PLGA showed 
higher DTH in immimized animals than the animals immunized with Free Cp or Cp 
emulsified with IF A (Fig.3.3.2) Also likewise liposome encapsulated Cp, the antigen 
entrapped in PLGA and that entrapped in PLGA and encapsulated in fibrin beads 
enhanced NO production in vaccinated animals (Fig. 3.3.3). Having more sustained 
degradability of PLGA and fibrin bead encapsulated PLGA lead to induction of high 
level of IFN-y (Fig3.3.4) and low level of IL-4 (Fig.3.3.5). Hence those two 
formulations provide better CMI response which is a prerequisite for candidiasis. 
PLGA and PLGA encapsulated in Fibrin beads containing Cp were also superior in 
enhancing lymphocyte proliferation as compared to the free form of the Cp or IFA-Cp 
(Fig.3.3.6). Protective immunity in animals immunized with soluble cytoplasmic 
antigen Cp was associated with the, lower secretion of IL-4 and increased serum 
levels of anti-Cp IgG along with IgG2a isotypes. 
Fib-PLGA-Cp based formulation upregulate costimulatory molecules present on the 
antigen presenfing cells (APCs) surface (Fig.3.3.7a and 3.3.7b). The results indicate 
high upregulation of co-stimulatory molecules in Fib-PLGA-Cp groups compared to 
other groups having sufficient stimulated T-cell population, which is a requisite for 
the development of a successfial candidate vaccine against intracellular pathogens like 
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C. albicans. In order to substantiate these results we further enumerated the CD4^ 
and CDS"" populations in splenocytes of the major vaccinated groups. 
The higher populations of CD4"^  and CD8"^  cells in the animals vaccinated with Fib-
PLGA-Cp formulation clearly demonstrate its efficacy in T cell proliferation 
(Fig.3.3.8a and 3.3.8b). The longer availability of antigen in host system we believe 
facilitates greater interaction of the antigen with APCs, which in turn assist their 
processing and presentation. The presented antigen on the surface of APCs that 
activate CD4^ and CD8^ cells in turn result in their maximum proliferation and 
differentiation. 
It is tempting to envision the advances in antimicrobial drug research that may obviate 
the need for complete understanding of microbial virulence and the discovery of 
antimicrobial agents that directly interfere with virulence factors, offer an interesting 
approach for new types of antimicrobial agents. However in humans, frequent use of 
antifungal chemotherapeutic drugs, specially azoles have evoked an emergence of 
resistant strains of C. albicans and fear of cross-resistance to other chemotherapeutic 
drugs (Sanglard et al., 1995). This situation argues strongly in favour of development 
of effective immunotherapy against various fungal infections including candidiasis. 
The fibrin-PLGA based vaccine could be one such potential candidate for combating 
atleast some fungal infections. 
The level of protection offered to animals immunized with Cp, IFA-Cp, PLGA-Cp, 
Fib-Cp, and Fib-PLGA-Cp was assessed by challenging the animals with Ix 10^  
viable C. albicans cells and monitoring their survival over a period of 30 days. We 
observed that Cp can induce remarkable protective immunity when administered 
entrapped in PLGA or Fib-PLGA (Fig.3.3.10). Further the protection of immunized 
animal was ascertained by measuring the fungal burden in the vital organs and blood 
of the animals. The reduction in fungal burden in the vital organs was in close 
agreement with survival of animals (Fig.3.3.1 la, 3.3.1 lb and 3.3.1 Ic). 
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